Nothing Special   »   [go: up one dir, main page]

EP2050460A1 - PYY et ses agonistes pour la modification du comportement d'alimentation - Google Patents

PYY et ses agonistes pour la modification du comportement d'alimentation Download PDF

Info

Publication number
EP2050460A1
EP2050460A1 EP20080022583 EP08022583A EP2050460A1 EP 2050460 A1 EP2050460 A1 EP 2050460A1 EP 20080022583 EP20080022583 EP 20080022583 EP 08022583 A EP08022583 A EP 08022583A EP 2050460 A1 EP2050460 A1 EP 2050460A1
Authority
EP
European Patent Office
Prior art keywords
pyy
seq
agonist
amino
npy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20080022583
Other languages
German (de)
English (en)
Inventor
Michael Cowley
Roger Cone
Malcolm Low
Andrew Butler
Stephen R. Bloom
Caroline J. Small
Rachael L. Batterham
Mohammad Ali Ghatei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Oregon Health Science University
Original Assignee
Imperial Innovations Ltd
Oregon Health Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0200507.2A external-priority patent/GB0200507D0/en
Application filed by Imperial Innovations Ltd, Oregon Health Science University filed Critical Imperial Innovations Ltd
Publication of EP2050460A1 publication Critical patent/EP2050460A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This application relates to the use of agents to control appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the field of obesity.
  • obesity is complex and multi-factorial. Increasing evidence suggests that obesity is not a simple problem of self-control but is a complex disorder involving appetite regulation and energy metabolism. In addition, obesity is associated with a variety of conditions associated with increased morbidity and mortality in a population. Although the etiology of obesity is not definitively established, genetic, metabolic, biochemical, cultural and psychosocial factors are believed to contribute. In general, obesity has been described as a condition in which excess body fat puts an individual at a health risk.
  • peripheral administration of PYY, or an agonist thereof, to a subject results in decreased food intake, caloric intake, and appetite, and an alteration in energy metabolism.
  • the subject can be any subject, including, but not limited to, a human subject.
  • the subject desires to lose weight, is obese, overweight, or suffers from a weight-related disorder.
  • PYY 3-36 can preferably be administered to the subject.
  • a method for decreasing calorie intake in a subject.
  • the method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.
  • a method for decreasing appetite in a subject includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the appetite of the subject.
  • a method for decreasing food intake in a subject includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the food intake of the subject.
  • a method for increasing energy expenditure in a subject.
  • the method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby increasing energy expenditure in the subject.
  • a method for decreasing calorie intake, food intake, or appetite in a human subject includes peripherally injecting a therapeutically effective amount of PYY or an agonist thereof in a pharmaceutically acceptable carrier to the subject in a pulse dose, thereby decreasing the calorie intake, food intake, or appetite of the subject.
  • the subject can be any subject, including, but not limited to, a human subject.
  • the subject desires to gain weight, is anorexic or cachexic.
  • nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
  • Action potential A rapidly propagated electrical message that speeds along an axon of a neuron and over the surface membrane of many muscle and glandular cells. In axons they are brief, travel at constant velocity, and maintain a constant amplitude.
  • the action potential is a membrane potential change caused by the flow of ions through ion channels in the membrane.
  • an action potential is a regenerative wave of sodium permeability.
  • Animal Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals.
  • anorexia A lack or loss of the appetite for food.
  • anorexia is a result of "anorexia nervosa.” This is an eating disorder primarily affecting females, usually with onset in adolescence, characterized by refusal to maintain a normal minimal body weight, intense fear of gaining weight or becoming obese, and a disturbance of body image resulting in a feeling of being fat or having fat in certain areas even when extremely emaciated, undue reliance on body weight or shape for self-evaluation, and amenorrhea.
  • Associated features often include denial of the illness and resistance to psychotherapy, depressive symptoms, markedly decreased libido, and obsessions or peculiar behavior regarding food, such as hoarding.
  • the disorder is divided into two subtypes, a restricting type, in which weight loss is achieved primarily through diet or exercise, and a binge-eating/purging type, in which binge eating or purging behavior also occur regularly.
  • Antagonist A substance that tends to nullify the action of another, as an agent that binds to a cell receptor without eliciting a biological response, blocking binding of substances that could elicit such responses.
  • Appetite A natural desire, or longing for food. In one embodiment, appetite is measured by a survey to assess the desire for food. Increased appetite generally leads to increased feeding behavior.
  • appetite suppressants Compounds that decrease the desire for food.
  • Commercially available appetite suppressants include, but are not limited to, amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine fenfluramine, dexfenfluramine, and fluoxetine.
  • Binding A specific interaction between two molecules, such that the two molecules interact. Binding can be specific and selective, so that one molecule is bound preferentially when compared to another molecule. In one embodiment, specific binding is identified by a disassociation constant (K d ).
  • BMI is calculated by dividing weight (in kg) by height 2 (in meters 2 ).
  • the current standards for both men and women accepted as "normal” are a BMI of 20-24.9 kg/m 2 .
  • a BMI of greater than 25 kg/m 2 can be used to identify an obese subject.
  • Grade I obesity corresponds to a BMI of 25-29.9 kg/m 2 .
  • Grade II obesity corresponds to a BMI of 30-40 kg/m 2 ; and Grade III obesity corresponds to a BMI greater than 40 kg/m 2 ( Jequier, Am. J Clin. Nutr. 45:1035-47, 1987 ).
  • Ideal body weight will vary among species and individuals based on height, body build, bone structure, and sex.
  • c-fos The cellular homologue of the viral v-fos oncogene found in FBJ (Finkel-Biskis-Jinkins) and FBR murine osteosarcoma viruses (MSV).
  • the human fos gene maps to chromosome 14q21-q31. Human fos has been identified as TIS-28.
  • C-fos is thought to have an important role in signal transduction, cell proliferation, and differentiation. It is a nuclear protein which, in combination with other transcription factors (for example, jun) acts as a trans-activating regulator of gene expression.
  • C-fos is an immediate early response gene, which are believed to play a key role in the early response of cells to growth factors.
  • C-fos is involved also in the control of cell growth and differentiation of embryonic hematopoietic cells and neuronal cells.
  • the human c-fos coding amino acid and nucleic sequences are known (e.g., see Verma et al., Cold Spring Harb. Symp. Quant. Biol. 51, 949, 1986; GenBank Accession Nos. K00650 and M16287, and is available on the internet).
  • Cachexia General physical wasting and malnutrition that is often associated with a chronic disease process. Cahexia is frequently seen in patients with cancer, AIDS, or other diseases.
  • Cachexia includes, but is not limited to 1) cancerous cachexia, seen in cases of malignant tumor; 2) cardiac cachexia, an emaciation due to heart disease, usually caused by a combination of increased caloric expenditure and decreased caloric intake or utilization; 3) fluoric cachexia, seen in fluorosis; 4) hypophysial cachexia; 5) cachexia hypophysiopriva, a cluster of symptoms resulting from total deprivation of function of the pituitary gland, including phthisis, loss of sexual function, atrophy of the pituitary target glands, bradycardia, hypothermia, apathy, and coma; 6) malarial cachexia, a group of physical signs of a chronic nature that result from antecedent attacks of severe malaria; 7) cachexia mercurialis, seen in chronic mercury poisioning; 8) pituitary cachexia; 9) saturnine cachexia, seen in chronic lead poisioning; 10) cachexia suprarenalis, associated with Addison's
  • Conservative variation The replacement of an amino acid residue by another, biologically similar residue.
  • conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like.
  • conservative variation also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
  • Non-limiting examples of conservative amino acid substitutions include those listed below: Original Residue Conservative Substitutions Ala Ser Arg Lys Asn Gln, His Asp Glu Cys Ser Gln Asn Glu Asp His Asn; Gln Ile Leu, Val Leu Ile; Val Lys Arg; Gln; Glu Met Leu; Ile Phe Met; Leu; Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp; Phe Val Ile; Leu Depolarization: An increase in the membrane potential of a cell. Certain stimuli reduce the charge across the plasma membrane. These can be electrical stimuli (which open voltage-gated channels), mechanical stimuli (which activate mechanically-gated channels) or certain neurotransmitters (which open ligand-gated channels).
  • EPP excitatory postsynaptic potential
  • Depolarizations can also be generated by decreasing the frequency of inhibitory postsynaptic currents (IPSCs), these are due to inhibitory neurotransmitters facilitating the influx of chloride ions into the cell, creating an IPSC. If the potential is increased to the threshold voltage (about -50 mV in mammalian neurons), an action potential is generated in the cell.
  • ISCs inhibitory postsynaptic currents
  • an action potential is generated in the cell.
  • Diabetes A failure of cells to transport endogenous glucose across their membranes either because of an endogenous deficiency of insulin and/or a defect in insulin sensitivity.
  • Diabetes is a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance. It occurs in two major forms: insulin-dependent diabetes mellitus (IDDM, type I) and non-insulin dependent diabetes mellitus (NIDDM, type II) which differ in etiology, pathology, genetics, age of onset, and treatment.
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin dependent diabetes mellitus
  • the two major forms of diabetes are both characterized by an inability to deliver insulin in an amount and with the precise timing that is needed for control of glucose homeostasis.
  • Diabetes type I, or insulin dependent diabetes mellitus (IDDM) is caused by the destruction of ⁇ cells, which results in insufficient levels of endogenous insulin.
  • Food intake The amount of food consumed by an individual. Food intake can be measured by volume or by weight. In one embodiment, food intake is the total amount of food consumed by an individual. In another embodiment, food intake is the amount of proteins, fat, carbohydrates, cholesterol, vitamins, minerals, or any other food component, of the individual. "Protein intake” refers to the amount of protein consumed by an individual. Similarly, “fat intake,” “carbohydrate intake,” “cholesterol intake,” “vitamin intake,” and “mineral intake” refer to the amount of proteins, fat, carbohydrates, cholesterol, vitamins, or minerals consumed by an individual.
  • Hyperpolarization A decrease in the membrane potential of a cell. Inhibitory neurotransmitters inhibit the transmission of nerve impulses via hyperpolarization. This hyperpolarization is called an inhibitory postsynaptic potential (IPSP). Although the threshold voltage of the cell is unchanged, a hyperpolarized cell requires a stronger excitatory stimulus to reach threshold.
  • Inhibitory Postsynaptic Current A current that inhibits an electrophysiological parameter of a postsynaptic cell. The potential of a postsynaptic cell can be analyzed to determine an effect on a presynaptic cell. In one embodiment, the postsynaptic cell is held in voltage clamp mode, and postsynaptic currents are recorded. If necessary, antagonists of other classes of current can be added.
  • IPSCs give a measure of the frequency of GABA release from an NPY neuron.
  • NPY neurons release GABA onto POMC neurons
  • measurement of IPSC frequency is a gauge of the inhibitory tone that POMC neurons are receiving, and can be used to assess the effect of an agonist of PYY.
  • Membrane potential The electrical potential of the interior of the cell with respect to the environment, such as an external bath solution. One of skill in the art can readily assess the membrane potential of a cell, such as by using conventional whole cell techniques.
  • Activation of a cell is associated with less negative membrane potentials (for example shifts from about -50 mV to about -40 mV). These changes in potential increase the likelihood of action potentials, and thus lead to an increase in the rate of action potentials.
  • the rate of action potentials can be assessed using many approaches, such as using conventional whole cell access, or using, for example, perforated-patch whole-cell and cell-attached configurations. In each event the absolute voltage or current is not assessed, rather the frequency of rapid deflections characteristic of action potentials is assessed, as a function of time (therefore this frequency is an instantaneous frequency, reported in "bins").
  • This time component can be related to the time at which a compound, such as a PYY agonist, is applied to the bath to analyze the effect of the compound, such as the PYY agonist, on action potential firing rate.
  • Neuropeptide Y A 36-amino acid peptide that is a neuropeptide identified in the mammalian brain. NPY is believed to be an important regulator in both the central and peripheral nervous systems and influences a diverse range of physiological parameters, including effects on psychomotor activity, food intake, central endocrine secretion, and vasoactivity in the cardiovascular system. High concentrations of NPY are found in the sympathetic nerves supplying the coronary, cerebral, and renal vasculature and have contributed to vasoconstriction.
  • NPY binding sites have been identified in a variety of tissues, including spleen, intestinal membranes, brain, aortic smooth muscle, kidney, testis, and placenta. In addition, binding sites have been reported in a number of rat and human cell lines.
  • Neuropeptide Y (NPY) receptor has structure/activity relationships within the pancreatic polypeptide family. This family includes NPY, which is synthesized primarily in neurons; peptide YY (PYY), which is synthesized primarily by endocrine cells in the gut; and pancreatic polypeptide (PP), which is synthesized primarily by endocrine cells in the pancreas.
  • NPY binds to several receptors, including the Y1, Y2, Y3, Y4 (PP), Y5, Y6, and Y7 receptors. These receptors are recognized based on binding affinities, pharmacology, and sequence (if known). Most, if not all of these receptors are G protein coupled receptors.
  • the Y1 receptor is generally considered to be postsynaptic and mediates many of the known actions of neuropeptide Y in the periphery.
  • this receptor was described as having poor affinity for C-terminal fragments of neuropeptide Y, such as the 13-36 fragment, but interacts with the full length neuropeptide Y and peptide YY with equal affinity (e.g., see PCT publication WO 93/09227 ).
  • the Y2 receptor is distinguished from Y1 by exhibiting affinity for C-terminal fragments of neuropeptide Y.
  • the Y2 receptor is most often differentiated by the affinity of neuropeptide Y(13-36), although the 3-36 fragment of neuropeptide Y and peptide YY provides improved affinity and selectivity (see Dumont et al., Society for Neuroscience Abstracts 19:726, 1993 ).
  • Y1 and the Y2 receptors are coupled to the inhibition of adenylate cyclase. Binding to the Y-2 receptor was also found to reduce the intracellular levels of calcium in the synapse by selective inhibition ofN-type calcium channels. In addition, the Y-2 receptor, like the Y1 receptors, exhibits differential coupling to second messengers (see U.S. Patent No. 6,355,478 ). Y2 receptors are found in a variety of brain regions, including the hippocampus, substantia nigra-lateralis, thalamus, hypothalamus, and brainstem.
  • a Y2 receptor agonist is a peptide, small molecule, or chemical compound that preferentially binds to the Y2 receptor and stimulates intracellular signaling.
  • an agonist for the Y2 receptor binds to the receptor with an equal or greater affinity than NPY.
  • an agonist selectively binds the Y2 receptor, as compared to binding to another receptor.
  • an assay such as a competition assay, is used to determine if a compound of interest is a Y2 receptor agonist.
  • Assays useful for evaluating neuropeptide Y receptor antagonists are also well known in the art (see U.S. Patent No. 5,284,839 , which is herein incorporated by reference, and Walker et al., Journal of Neurosciences 8:2438-2446, 1988 ).
  • a normal daily diet can be expressed in terms of caloric intake, protein intake, carbohydrate intake, and/or fat intake.
  • a normal daily diet in humans generally comprises the following: about 2,000, about 2,400, or about 2,800 to significantly more calories.
  • a normal daily diet in humans generally includes about 12 g to about 45 g of protein, about 120 g to about 610 g of carbohydrate, and about 11 g to about 90 g of fat.
  • a low calorie diet would be no more than about 85%, and preferably no more than about 70%, of the normal caloric intake of a human individual.
  • the caloric and nutrient requirements vary depending on the species and size of the animal.
  • the total caloric intake per pound, as well as the percent distribution of protein, carbohydrate and fat varies with the age of the cat and the reproductive state.
  • a general guideline for cats is 40 cal/lb/day (18.2 cal/kg/day).
  • About 30% to about 40% should be protein, about 7% to about 10% should be from carbohydrate, and about 50% to about 62.5% should be derived from fat intake.
  • One of skill in the art can readily identify the normal daily diet of an individual of any species.
  • Obesity A condition in which excess body fat may put a person at health risk (see Barlow and Dietz, Pediatrics 102:E29, 1998 ; National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Obes. Res. 6 (suppl. 2):51 S-209S, 1998 ). Excess body fat is a result of an imbalance of energy intake and energy expenditure.
  • the Body Mass Index (BMI) is used to assess obesity.
  • BMI Body Mass Index
  • a BMI of 25.0 kg/m 2 to 29.9 kg/m 2 is overweight, while a BMI of 30 kg/m 2 is obese.
  • waist circumference is used to assess obesity.
  • a waist circumference of 102 cm or more is considered obese, while in women a waist circumference of 89 cm or more is considered obese.
  • Strong evidence shows that obesity affects both the morbidity and mortality of individuals.
  • an obese individual is at increased risk for heart disease, non-insulin dependent (type 2) diabetes, hypertension, stroke, cancer (e.g. endometrial, breast, prostate, and colon cancer), dyslipidemia, gall bladder disease, sleep apnea, reduced fertility, and osteoarthritis, amongst others (see Lyznicki et al., Am. Fam. Phys. 63:2185,2001 ).
  • Overweight An individual who weighs more than their ideal body weight. An overweight individual can be obese, but is not necessarily obese.
  • an overweight individual is any individual who desires to decrease their weight.
  • an overweight individual is an individual with a BMI of 25.0 kg/m 2 to 29.9 kg/m 2
  • Pancreatic Polypeptide A 36 amino acid peptide produced by the pancreas that is has homology to PYY and NPY.
  • Peripheral Administration Administration outside of the central nervous system. Peripheral administration does not include direct administration to the brain. Peripheral administration includes, but is not limited to intravascular, intramuscular, subcutaneous, inhalation, oral, rectal, transdermal or intra-nasal administration
  • Polypeptide A polymer in which the monomers are amino acid residues which are joined together through amide bonds.
  • polypeptide or "protein” as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins.
  • polypeptide is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced.
  • polypeptide fragment refers to a portion of a polypeptide, for example such a fragment which exhibits at least one useful sequence in binding a receptor.
  • functional fragments of a polypeptide refers to all fragments of a polypeptide that retain an activity of the polypeptide.
  • Biologically functional peptides can also include fusion proteins, in which the peptide of interest has been fused to another peptide that does not decrease its desired activity.
  • PYY A peptide YY polypeptide obtained or derived from any species.
  • PYY includes the human full length polypeptide (as set forth in SEQ ID NO: 1) and species variations of PYY, including e.g. murine, hamster, chicken, bovine, rat, and dog PYY (SEQ ID NOS: 5-12).
  • PYY agonists do not include NPY.
  • PYYY also includes PYY 3-36 .
  • a "PYY agonist” is any compound which binds to a receptor that specifically binds PYY, and elicits an effect of PYY.
  • a PYY agonist is a compound that affects food intake, caloric intake, or appetite, and/or which binds specifically in a Y receptor assay or competes for binding with PYY, such as in a competitive binding assay with labeled PYY.
  • PYY agonists include, but are not limited to, compounds that bind to the Y2 receptor.
  • Substantially purified A polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
  • the polypeptide may be at least 50%, 80% or 90% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
  • Therapeutically effective amount A dose sufficient to prevent advancement, or to cause regression of a disorder, or which is capable of relieving a sign or symptom of a disorder, or which is capable of achieving a desired result.
  • a therapeutically effect of PYY or an agonist thereof is an amount sufficient to inhibit or halt weight gain, or an amount sufficient to decrease appetite, or an amount sufficient to reduce caloric intake or food intake or increase energy expenditure.
  • administration of PYY, or an agonist of PYY results in a decrease in the amount, either the total weight or the total volume of food.
  • administration of PYY, or an agonist thereof results in a decrease of the intake of a food component, such as a decrease in the ingestion of lipids, carbohydrates, cholesterol, or proteins.
  • a preferred compound, PYY 3-36 can be administered. This disclosure includes the corresponding uses of PYY or an agonist thereof for the manufacture of a medicament for the purposes set herein, and includes the use of PYY 3-36 .
  • a method is also disclosed herein for reducing caloric intake by peripherally administering to a subject a therapeutically effective amount of PYY or an agonist of PYY.
  • total caloric intake is reduced by peripheral administration of a therapeutically effective amount of PYY.
  • the caloric intake from the ingestion of a specific food component such as, but not limited to, the ingestion of lipids, carbohydrates, cholesterol, or proteins, is reduced.
  • a method for reducing appetite by administering a therapeutically effective amount of PYY or an agonist thereof.
  • Appetite can be measured by any means known to one of skill in the art.
  • decreased appetite can be assessed by a psychological assessment.
  • administration of PYY results in a change in perceived hunger, satiety, and/or fullness.
  • Hunger can be assessed by any means known to one of skill in the art.
  • hunger is assessed using psychological assays, such as by an assessment of hunger feelings and sensory perception using a questionnaire, such as, but not limited to, a Visual Analog Score (VAS) questionnaire (see the Examples section).
  • VAS Visual Analog Score
  • hunger is assessed by answering questions relating to desire for food, drink, prospective food consumption, nausea, and perceptions relating to smell or taste.
  • a method for altering energy metabolism in a subject.
  • the method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby altering energy expenditure.
  • Energy is burned in all physiological processes.
  • the body can alter the rate of energy expenditure directly, by modulating the efficiency of those processes, or changing the number and nature of processes that are occurring. For example, during digestion the body expends energy moving food through the bowel, and digesting food, and within cells, the efficiency of cellular metabolism can be altered to produce more or less heat.
  • a method is disclosed herein for any and all manipulations of the arcuate circuitry described in this application, that alter food intake coordinately and reciprocally alter energy expenditure.
  • Energy expenditure is a result of cellular metabolism, protein synthesis, metabolic rate, and calorie utilization.
  • peripheral administration of PYY results in increased energy expenditure, and decreased efficiency of calorie utilization.
  • a therapeutically effective amount of PYY or an agonist thereof is administered to a subject, thereby increasing energy expenditure.
  • PYY e.g., PYY 3-36
  • PYY e.g., PYY 3-36
  • the disclosure further relates to the use of PYY or an agonist thereof in control of any one or more of appetite, satiety and hunger, in particular any one or more of the following: reducing, suppressing and inhibiting appetite; inducing, increasing, enhancing and promoting satiety and sensations of satiety; and reducing, inhibiting and suppressing hunger and sensations of hunger.
  • the disclosure further relates to the use of PYY an agonist thereof in maintaining any one or more of a desired body weight, a desired Body Mass Index, a desired appearance and good health.
  • the subject can be any subject, including both human and veterinary mammalian subjects.
  • the subject can be a human, or can be a non-human primate, a farm animal such as swine, cattle, and poultry, a sport animal or pet such as dogs, cats, horses, hamsters, rodents, or a zoo animal such as lions, tigers, or bears.
  • Obesity is currently a poorly treatable, chronic, essentially intractable metabolic disorder.
  • a therapeutic drug useful in weight reduction of obese persons could have a profound beneficial effect on their health.
  • the subject can be, but is not limited to, a subject who is overweight or obese.
  • the subject has, or is at risk of having, a disorder wherein obesity or being overweight is a risk factor for the disorder.
  • disorders of interest include, but are not limited to, cardiovascular disease, (including, but not limited to, hypertension, atherosclerosis, congestive heart failure, and dyslipidemia), stroke, gallbladder disease, osteoarthritis, sleep apnea, reproductive disorders such as, but not limited to, polycystic ovarian syndrome, cancers (e.g., breast, prostate, colon, endometrial, kidney, and esophagus cancer), varicose veins, acnthosis nigricans, eczema, exercise intolerance, insulin resistance, hypertension hypercholesterolemia, cholithiasis, osteoarthritis, orthopedic injury, insulin resistance (such as, but not limited to, type 2 diabetes and syndrome X) and tromboembolic disease (see Kopelman, Nature 404:635-43 ; Rissanen et al., British Med. J. 301, 835, 1990 ).
  • cardiovascular disease including, but not limited to, hypertension, atheros
  • Obesity is a recognized risk factor for increased incidence of complications of general anesthesia. (See e. g., Kopelman, Nature 404:635-43, 2000 ). It reduces life span and carries a serious risk of co-morbidities listed above.
  • Other diseases or disorders associated with obesity are birth defects (maternal obesity associated with increased incidence of neural tube defects), carpal tunnel syndrome (CTS), chronic venous insufficiency (CVI), daytime sleepiness, deep vein thrombosis (DVT), end stage renal disease (ESRD), gout, heat disorders, impaired immune response, impaired respiratory function, infertility, liver disease, lower back pain, obstetric and gynecologic complications, pancreatititis, as well as abdominal hernias, acanthosis nigricans, endocrine abnormalities, chronic hypoxia and hypercapnia, dermatological effects, elephantitis, gastroesophageal reflux, heel spurs, lower extremity edema, mammegaly (causing considerable problems such as bra strap pain, skin damage, cervical pain, chronic odors and infections in the skin folds under the breasts, etc.), large anterior abdominal wall masses (abdominal panniculitis with frequent panniculitis, impeding walking, causing frequent infections,
  • condition or disorder which can be alleviated by reducing caloric (or nutrient) availability it is meant any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high nutrient availability, or that can be alleviated by reducing nutrient availability, for example by decreasing food intake.
  • Subjects who are insulin resistant, glucose intolerant, or have any form of diabetes mellitus (e.g., type 1, 2 or gestational diabetes) can also benefit from this disclosure.
  • Such conditions or disorders are disorders associated with increased caloric intake, insulin resistance, or glucose intolerance and include, but are not limited to, obesity, diabetes, including type 2 diabetes, eating disorders, insulin-resistance syndromes, and Alzheimer's disease.
  • the subject is a subject who desires weight loss, such as female and male subject who desire a change in their appearance.
  • the subject is a subject who desires decreased feelings of hunger, such as, but not limited to, a person involved in a lengthy task that requires a high level of concentration (e.g., soldiers on active duty, air traffic controllers, or truck drivers on long distance routes, etc.).
  • the present invention also relates the use of PYY or an antagonist thereof in the control of food intake in a mammal, in particular to increase, promote or stimulate food intake.
  • the disclosure also relates to the use of PYY or an antagonist thereof in weight control and treatment or prevention of wasting or anorexia, in particular any one or more of the following: inducing, promoting and increasing weight gain; reducing, inhibiting and preventing weight loss; and increasing body mass as measured by the Body Mass Index.
  • the invention further relates to the use of an antagonist of PYY or PYY 3-36 in control of any one or more of appetite, satiety and hunger, in particular any one or more of the following: increasing, inducing and promoting appetite; reducing, inhibiting or preventing satiety and sensations of satiety; and increasing, promoting and enhancing hunger and sensations of hunger.
  • an antagonist of PYY can be used in humans, companion animals and other objectively or subjectively valuable animals, for example, horses.
  • PYY antagonists can be used to stimulate appetite and increase weight gain when appetite is poor and weight is lost or may be lost.
  • Specific, non-limiting examples include during illness, after accidental or surgical trauma (for example, burns, and especially severe burns), during convalescence, in the elderly, and in anorexia and bulimia, and in other wasting conditions.
  • Appetite stimulation and increase in weight may be particularly desirable in specific conditions, for example, during cachexia (wasting) in AIDS, and in cancer patients.
  • a suitable administration format may be best determined by the subject or by a medical practitioner.
  • the pharmaceutical compositions that include PYY, or an agonist thereof, or an antagonist thereof will preferably be formulated in unit dosage form, suitable for individual administration of precise dosages.
  • An effective amount of PYY or an agonist thereof can be administered in a single dose, or in multiple doses, for example daily, during a course of treatment.
  • PYY is administered whenever the effect (e.g., appetite suppression, decreased food intake, or decreased caloric intake) is desired.
  • PYY or an analog thereof is administered slightly prior to whenever the effect is desired, such as, but not limited to about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, or about 120 minutes, prior to the time the effect is desired.
  • a time release formulation is utilized.
  • a therapeutically effective amount of PYY or an agonist thereof is administered as a single pulse dose, as a bolus dose, or as pulse doses administered over time.
  • a bolus administration of PYY is provided, followed by a time period wherein no PYY is administered to the subject, followed by a second bolus administration.
  • pulse doses of PYY are administered during the course of a day, during the course of a week, or during the course of a month.
  • the therapeutically effective amount of PYY or an agonist thereof will be dependent on the molecule utilized, the subject being treated, the severity and type of the affliction, and the manner of administration.
  • a therapeutically effective amount of PYY or an agonist thereof can vary from about 0.01 ⁇ g per kilogram (kg) body weight to about 1 g per kg body weight, such as about 1 ⁇ g to about 5 mg per kg body weight, or about 5 ⁇ g to about 1 mg per kg body weight.
  • PYY or an agonist thereof is administered to a subject at 0.5 to 135 picomole (pmol) per kg body weight, or about 72 pmol per kg body weight.
  • nmol is administered as a subcutaneous injection, such as about 2 to about 20 nmol, or about 10 nmol is administered as a subcutaneous injection.
  • the exact dose is readily determined by one of skill in the art based on the potency of the specific compound (such as the PYY polypeptide, or agonist) utilized, the age, weight, sex and physiological condition of the subject.
  • the dose of an agonist can be a molar equivalent of the therapeutically effective dose of PYY or PYY 3-36 .
  • compositions or pharmaceutical compositions can be administered by any route, including intravenous, intraperitoneal, subcutaneous, sublingual, transdermal, intramuscular, oral, topical, transmucosal, or by pulmonary inhalation.
  • Compositions useful in the disclosure may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous), nasal or oral administration.
  • parenteral refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
  • PYY including PYY 3-36 , an agonist of PYY, or an antagonist of PYY, can be administered subcutaneously. It is well known in the art that subcutaneous injections can be easily self-administered.
  • a PYY or a PYY agonist and another food-intake-reducing, plasma glucose-lowering or plasma lipid-altering agent in a single composition or solution for administration together.
  • a suitable administration format may best be determined by a medical practitioner for each patient individually.
  • Various pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin . See also Wang, Y. J. and Hanson, M. A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988 .
  • PYY, PYY agonists, and PYY antagonists useful in the methods of this disclosure can be provided as parenteral compositions, e.g., for injection or infusion.
  • they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to about 8.0, preferably at a pH of about 3.5 to about 7.4, 3.5 to 6.0, or 3.5 to about 5.0.
  • Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphoric acid, and sodium acetate/acetic acid buffers.
  • a form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.
  • the PYY and agonists are amphoteric, they may be utilized as free bases, as acid addition salts or as metal salts.
  • the salts must, of course, be pharmaceutically acceptable, and these will include metal salts, particularly alkali and alkaline earth metal salts, e.g., potassium or sodium salts.
  • metal salts particularly alkali and alkaline earth metal salts, e.g., potassium or sodium salts.
  • a wide variety of pharmaceutically acceptable acid addition salts are available. Such products are readily prepared by procedures well known to those skilled in the art.
  • compositions can be provided in dosage unit form containing an amount of a PYY or a PYY agonist with or without another active ingredient, e.g., a food intake-reducing, plasma glucose-lowering or plasma lipid-altering agent.
  • Administration may begin whenever the suppression of nutrient availability, food intake, weight, blood glucose or plasma lipid lowering is desired, for example, at the first sign of symptoms of a weight-related disorder or shortly after diagnosis of obesity, diabetes mellitus, or insulin resistance syndrome.
  • Therapeutically effective amounts of a PYY or a PYY agonist for use in reducing nutrient availability are those that suppress appetite at a desired level.
  • an effective amount of therapeutic agent will vary with many factors including the potency of the particular compound, age and weight of the patient, the patient's physical condition, the blood sugar level, the weight level to be obtained, and other factors.
  • therapeutically effective amounts of a PYY antagonist for use in increasing nutrient availability are those that increase appetite at a desired level.
  • an effective amount of this therapeutic agent will also vary with many factors including the potency of the particular compound, age and weight of the patient, the patient's physical condition, the blood sugar level, the weight level to be obtained, and other factors. Administration may begin whenever the increased of nutrient availability, food intake, weight, blood glucose or plasma lipid lowering is desired, such as, but not limited to, at the first sign of symptoms of a anorexia or at the onset of weight loss due to AIDS.
  • PYY, PYY agonists, and PYY antagonists are optimal formulation and mode of administration of PYY, PYY agonists, and PYY antagonists to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the PYY, PYY agonists, and PYY antagonists will typically be used to treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sport animals and pets such as horses, dogs and cats.
  • the PYY, PYY agonists, and PYY antagonists of the present disclosure may be administered directly by any suitable technique, including parenterally, intranasally, orally, or by absorption through the skin.
  • suitable technique including parenterally, intranasally, orally, or by absorption through the skin.
  • the specific route of administration of each agent will depend, e.g., on the medical history of the animal.
  • PYY, PYY agonists, and PYY antagonists can be formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • a pharmaceutically acceptable carrier refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to PYY and PYY agonists.
  • the formulations are prepared by contacting the PYY, PYY agonist, or PYY antagonist, uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
  • the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.
  • PPY, PYY antagonists, and PYY agonists are also suitably administered by sustained-release systems.
  • sustained-release PYY and PYY agonists include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).
  • Sustained-release PPY, PYY antagonist and PYY agonist compositions may be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray.
  • Sustained release matrices include polylactides ( U.S. Patent No. 3,773,919 , EP 58,481 ), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate ( Sidman et al., Biopolymers 22:547-556, 1983 , poly(2-hydroxyethyl methacrylate)); ( Langer et al., J. Biomed. Mater. Res. 15:167-277, 1981 ; Langer, Chem. Tech. 12:98-105, 1982 , ethylene vinyl acetate (Langer et al., Id .) or poly-D-(-)-3-hydroxybutyric acid ( EP 133,988 ).
  • polylactides U.S. Patent No. 3,773,919 , EP 58,481
  • copolymers of L-glutamic acid and gamma-ethyl-L-glutamate Sidman et al.,
  • Sustained-release PPY, PYY antagonists and PYY agonists include liposomally PPY and PYY agonists (see generally, Langer, Science 249:1527-1533, 1990 ; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317-327 and 353-365, 1989 ).
  • Liposomes containing PPY peptide and peptide analogs are prepared by methods known per se: DE 3,218,121 ; Epstein et al., Proc. Natl. Acad. Sci. U.S.A.
  • the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mole percent cholesterol, the selected proportion being adjusted for the optimal performance.
  • compositions for administration can be suitably formulated to give controlled release of PYY, PYY antagonists and PYY agonists.
  • the pharmaceutical compositions may be in the form of particles comprising a biodegradable polymer and/or a polysaccharide jellifying and/or bioadhesive polymer, an amphiphilic polymer, an agent modifying the interface properties of the particles and a pharmacologically active substance. These compositions exhibit certain biocompatibility features which allow a controlled release of the active substance. See U.S. Patent No. 5,700,486 .
  • PPY, PYY antagonists, and PYY agonists are delivered by way of a pump (see Langer, supra ; Sefton, CRC Crit. Ref Biomed. Eng. 14:201, 1987 ; Buchwald et al., Surgery 88:507, 1980 ; Saudek et al., N. Engl. J. Med. 321:574, 1989 ) or by continuous subcutaneous infusions, for example, using a mini-pump.
  • An intravenous bag solution may also be employed.
  • the key factor in selecting an appropriate dose is the result obtained, as measured by decreases in total body weight or ratio of fat to lean mass, or by other criteria for measuring control or prevention of obesity or prevention of obesity-related conditions, as are deemed appropriate by the practitioner.
  • Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533, 1990 ).
  • PPY, PYY antagonists, and PYY agonists are delivered by way of an implanted pump, described, for example, in U.S. Patent No. 6,436,091 ; U.S. Patent No. 5,939,380 ; U.S. Patent No. 5,993,414 .
  • Implantable drug infusion devices are used to provide patients with a constant and long term dosage or infusion of a drug or any other therapeutic agent. Essentially such device may be categorized as either active or passive.
  • Active drug or programmable infusion devices feature a pump or a metering system to deliver the drug into the patient's system.
  • An example of such an active drug infusion device currently available is the Medtronic SynchroMedTM programmable pump.
  • Such pumps typically include a drug reservoir, a peristaltic pump to pump out the drug from the reservoir, and a catheter port to transport the pumped out drug from the reservoir via the pump to a patient's anatomy.
  • Such devices also typically include a battery to power the pump as well as an electronic module to control the flow rate of the pump.
  • the Medtronic SynchroMedTM pump further includes an antenna to permit the remote programming of the pump. Passive drug infusion devices, in contrast, do not feature a pump, but rather rely upon a pressurized drug reservoir to deliver the drug.
  • Such devices tend to be both smaller as well as cheaper as compared to active devices.
  • An example of such a device includes the Medtronic IsoMedTM. This device delivers the drug into the patient through the force provided by a pressurized reservoir applied across a flow control unit.
  • the implanted pump can be completely implanted under the skin of a patient, thereby negating the need for a percutaneous catheter.
  • These implanted pumps can provide the patient with PYY, PYY antagonist, or a PYY agonist at a constant or a programmed delivery rate, e.g., to give pulsed doses at or around meal time.
  • Constant rate or programmable rate pumps are based on either phase-change or peristaltic technology. When a constant, unchanging delivery rate is required, a constant-rate pump is well suited for long-term implanted drug delivery. If changes to the infusion rate are expected, a programmable pump may be used in place of the constant rate pump system. Osmotic pumps may be much smaller than other constant rate or programmable pumps, because their infusion rate can be very low. An example of such a pump is described listed in U.S. Patent No. 5,728,396 .
  • the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato starch
  • Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • the preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
  • the compounds for use according to the present disclosure are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or
  • the compounds can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions that comprise a PYY, or an agonist thereof, or a PYY antagonist, as described herein as an active ingredient will normally be formulated with an appropriate solid or liquid carrier, depending upon the particular mode of administration chosen.
  • the pharmaceutically acceptable carriers and excipients useful in this disclosure are conventional.
  • parenteral formulations usually comprise injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like.
  • Excipients that can be included are, for instance, other proteins, such as human serum albumin or plasma preparations.
  • the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • Other medicinal and pharmaceutical agents for instance other appetite suppressants, or protease inhibitors, also may be included. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art.
  • the dosage form of the pharmaceutical composition will be determined by the mode of administration chosen. For instance, in addition to injectable fluids, inhalation, suppository, and oral formulations can be employed.
  • the pharmaceutical compositions can be produced of conventional mixing, granulating, confectioning, dissolving or lyophilizing processes.
  • Oral formulations may be liquid (e.g., syrups, solutions or suspensions), or solid (e.g., powders, pills, tablets, or capsules).
  • pharmaceutical compositions for oral use can be obtained by combining the active ingredient with one or more solid carriers, optionally granulating a resulting mixture, and, if desired, processing the mixture or granules, if appropriate with the addition of additional excipients, to form tablets or dragee cores.
  • Suitable carriers include fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyffolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, cross-linked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate.
  • Additional excipients include flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
  • compositions include suitable aqueous solutions of an active ingredient in water-soluble form, for example in the form of a water-soluble salt, or aqueous injection suspensions that contain viscosity-altering substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers.
  • the active ingredient optionally together with excipients, can also be in the form of a lyophilisate and can be made into a solution prior to parenteral administration by the addition of suitable solvents. Solutions such as those that are used, for example, for parenteral administration can also be used as infusion solutions.
  • PYY or an agonist thereof, or a PYY antagonist is administered as an aerosol or a dispersion in a carrier.
  • PYY or an agonist thereof is administered as an aerosol from a conventional valve, such as, but not limited to, a metered dose valve, through an aerosol adapter also known as an actuator.
  • a suitable fluid carrier can be also included in the formulation, such as, but not limited to, air, a hydrocarbon, such as n-butane, propane, isopentane, amongst others, or a propellant, such as, but not limited to a fluorocarbon.
  • a stabilizer is also included, and/or porous particles for deep lung delivery are included (e.g., see U.S. Patent No. 6,447,743 ).
  • an inhalation formulation for a sustained release includes using aerosol droplet particles approximately 1-2.1 ⁇ m in size, or of less than 1 ⁇ m in size. Small particle aerosol liposomes and liposome-drug combinations for medical use have been previously described (e.g., see EP 87309854.5 ).
  • a therapeutically effective amount of PYY or an agonist thereof is administered with a therapeutically effective amount of another agent, such as, but not limited to, an additional appetite suppressant.
  • an additional appetite suppressant include amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine, fenfluramine, dexfenfluramine, and fluoxetine.
  • PYY and/or a PYY agonist can be administered simultaneously with the additional appetite suppressant, or they may be administered sequentially.
  • PYY is formulated and administered with an appetite suppressant as a single dose.
  • a method of treating obesity includes administering to an obese subject a therapeutically effective amount of PYY or a PYY agonist.
  • the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
  • PYY and/or the PYY agonist can be administered peripherally, such as in a single or divided dose. Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg per dose.
  • the subject can be insulin resistant or glucose intolerant, or both. In addition to being obese, the subject can have diabetes mellitus.
  • a method of reducing food intake includes administering to an obese subject a therapeutically effective amount of PYY or a PYY agonist.
  • the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
  • PYY and/or the PYY agonist can be administered peripherally, such as in a single or divided dose. Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg per dose.
  • the subject can have Type II diabetes, and/or can be overweight.
  • a method for improving lipid profile in a subject includes administering to the subject an effective amount of PYY or a PYY agonist.
  • An improvement in lipid profile includes, but is not limited to, at least one of reducing cholesterol levels, reducing triglyceride levels and increasing HDL cholesterol levels.
  • PYY and/or the PYY agonist can be administered peripherally, such as in a single or divided dose.
  • PYY and/or the PYY agonist can be administered peripherally, such as in a single or divided dose. Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg per dose.
  • the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
  • a method for alleviating a condition or disorder which can be alleviated by reducing nutrient availability.
  • the method includes administering to a subject a therapeutically effective amount of PYY or a PYY agonist.
  • Suitable disorders include any of the disorders mentioned above.
  • PYY and/or the PYY agonist can be administered peripherally, such as in a single or divided dose. Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg per dose.
  • the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
  • Suitable doses also include those that raise the concentration of PYY and/or the agonist thereof significantly above the basal concentration of PYY, such as, but not limited to, a dose that that mimic postparandial serum concentrations of PYY (or the agonist).
  • PYY or an agonist thereof is administered to achieve the level of to effect a reduction in calorie intake, food intake, or appetite equivalent to the reduction in calorie intake, food intake, or appetite, or to increase the energy expenditure, caused by the postprandial level of PYY3-36.
  • doses include, but are not limited doses that produce the effect demonstrated when the serum levels of PYY are from about 40 pM to about 50 pM, or from about 40 pM to about 45 pM, or to about 43 pM.
  • the dose of PYY or PYY 3-36 can be based on the physiological levels observed post-prandially.
  • the normal circulating levels of PYY 3-36 are about 8 pmol/litre, typically rising to about 40 to 60 pmol/litre after a meal.
  • Agonists of PYY can be used at analogous doses.
  • a single dose may be administered per day, or divided doses can be used (see above).
  • PYY 3-36 has been shown to be effective for up to 12 and even for up to 24 hours after administration, it is possible to administer only two or even just one doe per day.
  • PYY when administered peripherally, PYY, including PYY 3-36 has its effects at physiological levels.
  • Other gut hormones e.g., GLP
  • GLP gut hormones
  • PYY 3-36 does not affect Y2 receptors throughout the brain, which could cause side effects.
  • PYY 3-36 does not increase blood pressure.
  • the effects of PYY 3-36 are as long lasting as 24 hours. Recipients claim a decrease in appetite over that period, and a reduction of food intake of about one third has been reported.
  • PYY 3-36 is administered in a dose of about 1 nmol or more, 2 nmol or more, or 5 nmol or more.
  • the dose of PYY 3-36 is generally not more than 100 nmol, for example, the dose is 90 nmols or less, 80 nmols or less, 70 nmols or less, 60 nmols or less, 50 nmols or less, 40 nmols or less, 30 nmols or less, 20 nmols or less, 10 nmols.
  • a dosage range may comprise any combination of any of the specified lower dose limits with any of the specified upper dose limits.
  • exemplar non-limiting dose ranges include a dose of PYY 3-36 may be within the range of form 1 to 100 n mols, from 1 to 90 mols, from 1 to 80 nmols.
  • exemplary, non-limiting dose ranges include, from 2 to 100 nmols, from 2 to 90 n mols, for example, from 2 to 80 nmols etc., from 5 nmols to 100 mols, from 5 nmols to 90 nmols, from 5 nmols to 80 nmols etc.
  • a dose of from about 5 to about 50 nmol may be administered such as, but not limited to, from about 2 to about 20 nmol, for example, about 10 nmol.
  • the selected dose may be administered for example, by injection, for example, as a subcutaneous injection.
  • a dose of PYY or PYY 3-36 at 0.143 n moles (1/7 th of a mole) is administered per kilogram, to achieve a dose that is similar to the postparandial level of PYY.
  • the dose is preferably a molar equivalent of a PYY 3-36 dose, as described above.
  • the doses can be calculated on the basis of a subject, such as a subject weighing from 70 to 75 kg. The exact dose is readily determined by one of skill in the art based on the potency of the specific compound (such as the PYY polypeptide, or agonist) utilized, and the age, weight, sex and physiological condition of the subject.
  • a naturally occurring peptide PYY or PYY 3-36 can be used to achieve a physiological effect. This results in minimal side effects and enables long term use, if necessary.
  • the dose of PYY or PYY 3-36 can be based on the physiological levels observed post-prandially.
  • the normal circulating levels of PYY 3-36 are about 8 pmol/litre, typically rising to about 40 to 60 pmol/litre after a meal.
  • PYY e.g., PYY 3-36
  • agonists can be used at analogous doses.
  • PYY e.g., PYY 3-36
  • PYY e.g., PYY 3-36
  • Some of the treatments described above are medical treatments, for example, the treatment of obesity. Others, however, do not relate to medical treatment, and are part of the maintenance of a healthy lifestyle, or are for cosmetic purposes.
  • a PYY agonist of use in the methods of the present disclosure, is a molecule that binds to a receptor that specifically binds PYY, and elicits an effect of PYY.
  • Assays for binding to PYY receptors, and eliciting a response in a cell with a PYY receptor, are known in the art.
  • a specific assay for detecting a PYY agonist is also disclosed herein.
  • a PYY agonist binds to a NPY neuron in the arcuate nucleus, which results in an electrophysiological effect on an NPY neuron.
  • NPY neurons synapse with POMC neurons.
  • the electrophysiological effect on the NYP neuron can result in a further electrophysiological effect on a POMC neuron.
  • an administration of PYY agonist results in hyperpolization of the membrane potential of a POMC neuron.
  • administration of a PYY agonist results in an increase in IPSCs in a POMC neuron.
  • PYY agonists do not include NPY.
  • Suitable PYY agonists include molecules that bind NPY neurons, but do not cross the blood/brain barrier.
  • the arcuate nucleus neurons upon which PYY exerts its effects are not protected by the blood/brain barrier, and thus are readily accessible to peripherally available molecules.
  • other brain sites that express the Y2 receptor are protected by the blood/brain barrier.
  • agents able to bind to the arcuate Y2R, but that do not cross the blood/brain barrier following peripheral administration are likely to be of use.
  • a PYY agonist is a compound that affects food intake, caloric intake, or appetite, and/or which binds specifically in a Y receptor assay or competes for binding with PYY, such as in a competitive binding assay with labeled PYY.
  • PYY agonists include, but are not limited to, compounds that bind to the Y2 receptor.
  • PYY and agonists useful in the methods disclosed herein include, but are not limited to, polypeptides comprising, or alternatively consisting of, the amino acid sequence for PPY and agonists thereof, e.g., mutants, fragments and/or variants thereof.
  • Variants include deletions, insertions, inversions, repeats and substitutions (e.g., conservative substitutions and non-conservative substitutions; see, e.g., Tables 1 and 2, infra ) .
  • More than one amino acid e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.
  • conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of Ser and Thr containing hydroxy residues, interchange of the acidic residues Asp and Glu, interchange between the amide residues Asn and Gln, interchange of the basic residues Lys and Arg, interchange of the aromatic residues Phe and Tyr, and interchange of the small-sized amino acids Ala, Ser, Thr, Met and Gly.
  • Guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310, 1990 .
  • polypeptide fragments may contain a continuous series of deleted residues from the amino (N)- or the carboxyl (C)- terminus, or both (see, e.g., Tables 1 and 2, infra ) . Any number of amino acids, ranging from 1 to 24, can be deleted from the N-terminus, the C-terminus or both.
  • the agonist polypeptides may also include, but are not limited to, polypeptides comprising, or alternatively consisting of, internal deletions of the amino acid sequences for PPY and/or agonist thereof (see, e.g., Table 2, infra ). Such deletions may comprise one or more amino acid residue deletions (e.g., one, two, three, four, five, six, seven, eight, nine, ten, etc.) and may begin at any amino acid position (e.g., two, three, four, five, six, seven, eight, nine, ten, etc.).
  • the polypeptides of this disclosure may contain one or more such internal deletions. Such deletions are contemplated in PPY, NPY and PP.
  • agonist peptides that are PPY, NPY and/or PP chimeras having high affinity and/or selectivity for the Y2 receptor.
  • These chimeras may comprise amino acid substitutions of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) from PPY, NPY and/or PP, variants, mutants and/or deletions thereof, with one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) from a second PPY, NPY, or PP, variants, mutations and/or deletions thereof.
  • substitutions may begin at any amino acid position (e.g., two, three, four, five, six, seven, eight, nine, ten, etc.).
  • the peptide is selective for the Y2 receptor. That is, it binds with higher affinity to Y2 compared to other receptors, such as Y1, Y2, Y3, Y4, Y5 and Y6.
  • the peptide is selective for the Y2 and Y5 receptors over the Y1, Y3, Y4 and Y6 receptors.
  • polypeptide fragments are fragments comprising structural or functional domain of the polypeptides of this disclosure.
  • Such fragments include amino acid residues that comprise a polyproline-type II helix (residues 1-8), beta-turn (residues 9-14), amphipathic alpha-helix (residues 15-32) and/or a C-terminal turn structure (residues 33-36). See, Kirby et al., J Med Chem 36:385-393, 1993 .
  • this disclosure includes the use of a polypeptide or agonist comprising, or alternatively consisting of, the amino acid sequence for PPY, NPY and PP species variants (see Table 1, infra ) and/or mutants, and fragments thereof.
  • fusion proteins whereby a PYY or PYY agonist will be fused to another protein or polypeptide (the fusion partner) using recombinant methods known in the art.
  • a fusion protein may be synthetically synthesized by any known method. Any known peptide or protein can be used as the fusion partner (e.g., serum albumin, carbonic anhydrase, glutathione-S-transferase or thioredoxin, etc.).
  • Preferred fusion partners will not have an adverse biological activity in vivo.
  • Such fusion proteins may be designed linking the carboxy-terminus of the fusion partner to the amino-terminus of the PYY or agonist peptide, or vice versa.
  • a cleavable linker region may be used linking the PYY or PYY agonist to the fusion partner, and may be cleaved in vivo thereby resulting in the release of an active form of PYY or a PYY agonist.
  • cleavage regions include, but are not limited to, the linker regions D-D-D-D-Y (SEQ ID NO: 330), G-P-R (SEQ ID NO: 331), A-G-G (SEQ ID NO: 332) and H-P-F-H-L (SEQ ID NO 333), which can be cleaved by enterokinase, thrombin, ubiquitin cleaving enzyme and renin, respectfully.
  • PYY agonists are Y2 specific NPY peptide agonists as described in U.S. Patent No. 5,026,685 ; U.S. Patent No. 5,574,010 ; U.S. Patent No. 5,604,203 ; U.S. Patent No. 5,696,093 ; U.S. Patent No. 6,046,167 . See below:
  • Preferred PPY agonists are described herein as follows.
  • PYY including but not limited to: PYY(26-36), PYY(25-36), PYY(24-36), PYY(23-36), PYY(22-36), PYY(21-36), PYY(20-36), PYY(19-36), PYY(18-36), PYY(17-36), PYY(16-36), PYY(15-36), PYY(14-36), PYY(13-36), PYY(12-36), PYY(11-36), PYY(10-36), PYY(9-36), PYY(8-36), PYY(7-36), PYY(6-36), PYY(5-36), PYY(4-36), PYY(3-36).
  • PEPTIDE SEQUENCE NPY (human) YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY (SEQ ID NO:2) Ref: Tatemoto et al., Proc Natl Acad Sci U.S.A. 79:5485-9, 1982 .
  • N-Terminal Deletions of NPY including but not limited to: NPY(26-36), NPY(25-36), NPY(24-36), NPY(23-36), NPY(22-36), NPY(21-36), NPY(20-36), NPY(19-36), NPY(18-36), NPY(17-36), NPY(16-36), NPY(15-36), NPY(14-36), NPY(13-36), NPY(12-36), NPY(11-36), NPY(10-36), NPY(9-36), NPY(8-36), NPY(7-36), NPY(6-36), NPY(5-36), NPY(4-36), NPY(3-36).
  • Ref See e.g., Gehlert et al., Proc Soc Exp Biol Med 218:7-22, 1998 ; Sheikh et al.,
  • Internal Deletions including but not limited to: (1-4)-Aca-(14-36)pNPY, (1-4)-Aca-(15-36)pNPY, (1-4)-Aca-(16-36)pNPY, (1-4)-Aca-(17-36)pNPY, (1-4)-Aca-(18-36)pNPY, (1-4)-(31-36)pNPY11, (1-4)-Aca-(31-36)pNPY, (4-1)-(31-36)pNPY, (4-1)-Aca-(31-36)pNPY, (4-1) D -(31-36)pNPY, (4-1) D -Aca-(31-36)pNPY.
  • Ref Fournier et al., Mol Pharmacol 45(1):93-101, Jan 1994 .
  • Cyclic agonist of NPY including but not limited to: [Lys 25-Glu 29]NPY(Ac-25-36), [Glu 25-Lys 29]NPY(Ac-25-36), [Lys 26-Glu31]NPY(Ac-25-36), [Glu 27-Lys 31]NPY(Ac-25-36), [Lys28-Glu 32]NPY(Ac-25-36), [Lys27-Glu34]NPY(Ac-25-36). Ref: Rist et al., Eur J Biochem 247:1019-1028, 1997 .
  • D-amino acid substitutions [D-Tyr 1 ]NPY, [D-Pro 2 ]NPY, [D-Ser 3 ]NPY, [D-Lys 4 ]NPY, [D-Pro 5 ]NPY, [D-Asp 6 ]NPY, [D-Asn 7 ]NPY, [D-Pro 8 ]NPY, [D-Ala 9 ]NPY, [D-Glu 10 ]NPY, [D-Asp 11 ]NPY, [D-Ala 12 ]NPY, [D-Pro 13 ]NPY, [D-Ala 14 ]NPY, [D-Glu 15 ]NPY, [D-Asp 16 ]NPY, [D-Leu 17 ]NPY, [D-Ala 18 ]NPY, [D-Arg 19 ]NPY, [D-Tyr 20 ]NPY, [D-Tyr 21 ]NPY, [D-Ser 22 ]NPY, [D-
  • PEPTIDE SEQUENCE NPY(3-36) SKPDNPGEDAPAEDMARYYSALRHYINLITRQRY (SEQ ID NO: 335) Ref: Grandt et al., Regulatory Peptides 67(1):33-7, 1996 .
  • PEPTIDE SEQUENCE N-Acetyl NPY(24-36) LRHYINLITRQRY (SEQ ID NO: 213) Ref: Potter et al., Eur J Pharmacol 267(3):253-262, May 17, 1994 .
  • PEPTIDE SEQUENCE N-Acetyl [Leu 28 , Leu 31 ] NPY(24-36) LRHYLNLLTRQRY (SEQ ID NO: 214) Ref: Potter et al., Eur J Pharmacol 267(3):253-262, May 17, 1994 .
  • PEPTIDE SEQUENCE [Leu 28 , Leu 31 ] NPY(24-36) LRHYLNLLTRQRY (SEQ ID NO: 215) Ref: Potter et al., Eur J Pharmacol 267(3):253-262, May 17, 1994 .
  • PEPTIDE SEQUENCE [Leu 17 , Gln 19 , Ala 21 , Ala 22 , Glu 23 , Leu 28 , Leu 31 ] NPY(13-36) PAEDLAQYAAELRHYLNLLTRQRY (SEQ ID NO: 216) Ref: Potter et al., Eur J Pharmacol 267(3):253-262, May 17, 1994 .
  • PEPTIDE SEQUENCE Cyclo S-S [Cys 20 ,Cys 24 ]pNPY SKPDNPGEDAPAEDMARCYSACRHYINLITRQRY (SEQ ID NO: 315) Ref: Soll et al., Eur J Biochem 268(10):2828-37, May 2001 .
  • PEPTIDE SEQUENCE Cyclo-(28/32)-Ac-[Lys 28 -Glu 32 ]-(25-36)-pNPY RHYLNLIGRQRY (SEQ ID NO: 316) Ref: Cabrele et al., J Pept Sci 6(3):97-122, Mar 2000 .
  • PEPTIDE SEQUENCE Cyclo-(27/31)-Ac-[Glu 27 -Lys 31 ]-(25-36)-pNPY RHGLNLLGRQRY (SEQ ID NO: 317) Ref: Cabrele et al., J Pept Sci 6(3):97-122, Mar 2000 .
  • N-Terminal Deletions including but not limited to: PP(26-36), PP(25-36), PP(24-36), PP(23-36), PP(22-36), PP(21-36), PP(20-36), PP(19-36), PP(18-36), PP(17-36), PP(16-36), PP(15-36), PP(14-36), PP(13-36), PP(12-36), PP(11-36), PP(10-36), PP(9-36), PP(8-36), PP(7-36), PP(6-36), PP(5-36), PP(4-36), PP(3-36).
  • PYY(23-36) PEPTIDE SEQUENCE PYY(23-36) SLRHYLNLVTRQRY (SEQ ID NO: 148) [Thr 23 ]PYY(23-36) TLRHYLNLVTRQRY (SEQ ID NO: 149)
  • PYY(22-36) PEPTIDE SEQUENCE PYY(22-36) ASLRHYLNLVTRQRY (SEQ ID NO: 150) [Ser 22 )PYY(22-36) SSLRHYLNLVTRQRY (SEQ ID NO: 151)
  • PYY(21-36) Point Mutations of PYY(21-36) PEPTIDE SEQUENCE PYY(21-36) YASLRHYLNLVTRQRY (SEQ ID NO: 152) [Thr 21 ]PYY(21-36) TASLRHYLNLVTRQRY (SEQ ID NO: 153) [Phe 21 ]PYY(21-36) FASLRHYLNLVTRQRY (SEQ ID NO: 154)
  • PYY(20-36) PEPTIDE SEQUENCE PYY(20-36) YYASLRHYLNLVTRQRY (SEQ ID NO: 155) [Thr 20 ]PYY(20-36) TYASLRHYLNLVTRQRY (SEQ ID NO: 156) [Phe 20 ]PYY(20-36) FYASLRHYLNLVTRQRY (SEQ ID NO: 157)
  • PYY(19-36) PEPTIDE SEQUENCE PYY(19-36) RYYASLRHYLNLVTRQRY (SEQ ID NO: 158) [Lys 19 ]PYY(19-36) KYYASLRHYLNLVTRQRY (SEQ ID NO: 159)
  • PYY(18-36) PEPTIDE SEQUENCE PYY(18-36) NRYYASLRHYLNLVTRQRY (SEQ ID NO: 160) [Gln 18 ]PYY(18-36) QRYYASLRHYLNLVTRQRY (SEQ ID NO: 161)
  • PYY(17-36) PEPTIDE SEQUENCE PYY(17-36) LNRYYASLRHYLNLVTRQRY (SEQ ID NO: 162) [Ile 17 ]PYY(17-36) INRYYASLRHYLNLVTRQRY (SEQ ID NO: 163) [Val 17 ]PYY(17-36) VNRYYASLRHYLNLVTRQRY (SEQ ID NO: 164)
  • PYY(16-36) PEPTIDE SEQUENCE PYY(16-36) ELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 165) [Asp 16 ]pyy(16-36) DLNRYYASLRHYLNLVTRQRY (SEQ ID NO: 166)
  • PYY(15-36) PEPTIDE SEQUENCE PYY(15-36) EELNRYYASLRHYLNLVTRQRY (SEQ ID NO:167) [Asp 15 ]PYY(15-36) DELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 168)
  • PYY(13-36) PEPTIDE SEQUENCE PYY(13-36) SPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 170) [Thr 13 ]PYY(13-36) TPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 171)
  • PYY(12-36) PEPTIDE SEQUENCE PYY(12-36) ASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 172) [Ser 12 ]PYY(12-36) SSPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 173)
  • PYY(11-36) PEPTIDE SEQUENCE PYY(11-36) DASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 174) [Glu 11 ]PYY(11-36) EASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 175)
  • PYY(10-36) PEPTIDE SEQUENCE PYY(10-36) EDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 176) [Asp 10 ]PYY(10-36) DDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 177)
  • PYY(7-36) PEPTIDE SEQUENCE PYY(7-36) APGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 180) [Ser 9 ]PYY(7-36) SPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 181)
  • PYY(6-36) PEPTIDE SEQUENCE PYY(6-36) EAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 182) [Asp 6 ]PYY(6-36) DAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 183)
  • PYY(4-36) PEPTIDE SEQUENCE PYY(4-26) KPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 185) [Arg 4 ]PYY(4-36) RPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 186) [Gln 4 ]PYY(4-36) QPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 187) [Asn 4 ]PYY(4-36) NPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 188)
  • PYY(3-36) PEPTIDE SEQUENCE PYY(3-36) IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 1) [Leu 3 ]PYY(3-36) LKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 189) [Val 3 ] PYY(3-36) VKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 190)
  • PYY agonists having the formula: wherein X is H or C a Me or N a Me or desamino or an acyl group having 7 carbon atoms or less; Q is R 17 -R 18 , R 18 or desQ; R 17 is Met, Arg, Nle, Nva, Leu, Ala or D-Ala; R 18 is Ala, Ser, Ile, D-Ala, D-Ser or D-Ile; R 19 is Arg, Lys or Gln; R 20 is Tyr or Phe; R 21 is Tyr, Glu, His or Ala; R 22 is Ser, Ala, Thr, Asn or Asp; R 23 is Ala, Asp, Glu, Gln, Asn or Ser; R 25 is Arg or Gln; R 26 is His, Arg or Gln; R 27 is Phe or Tyr; R 28 is Ile, Leu, Val or Arg; R 29 is Asn or Ile; R 30 is Leu,
  • Certain preferred NPY analogs have the formula: X-R 18 -Arg-Tyr-Tyr-R 22 -R 23 -Leu-Arg-His-Tyr-R 28 -Asn-Leu-R 31 -Thr-Arg-Gln-Arg-Tyr-NH 2 , wherein X is H or C a Me or N a Me or desamino or an acyl group having 7 carbon atoms or less; R 18 is Ala or Ser; R 22 is Ser or Ala; R 23 is Ala or Ser; R 27 is Phe or Tyr; R 28 is Ile or Leu; R 31 is Ile or Val; and R 36 is Phe or Tyr; provided that at least one of R 27 and R 36 is Phe. See U.S. Patent No. 5,026,685 .
  • NPY analogs have the formula: wherein R 17 is Arg or Leu and R 18 is Ser or Ala or Ile; and wherein X, R 27 and R 36 are as previously indicated.
  • Still other preferred NPY analogs have the formula: wherein X is desamino or C a Me or N a Me and wherein R 18 , R 25 , R 27 and R 36 are as previously indicated.
  • NPY agonists examples include:
  • Particularly preferred agonists of this formula to be used in the method of the disclosure include: N- ⁇ -Ala-Ser-Leu-Arg-His-Trp-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ ID NO: 255).
  • PYY agonists have the formula: wherein:
  • a 27 is Phe, Nal, Bip, Pcp, Tic, Trp, Bth, Thi, or Dip.
  • X is A 17 -A 18 -A 19 -A 20 -A 21 wherein A 17 is Cys, Leu, Ile, Val, Nle, Nva, Aib, Anb, or N-Me-Leu; A 18 is Cys, Ser, Thr, N-Me-Ser, or N-Me-Thr; A 19 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or C 6 -C 18 aryl group), Cys, or Om; A 20 is an aromatic amino acid, or Cys; and A 21 is an aromatic amino acid, Cys, or a pharmaceutically acceptable salt thereof.
  • Y is A 33 -A 34 -A 35 -A 36 wherein A 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or an aryl group), Cys, or Om; A 34 is Cys, Gln, Asn, Ala, Gly, N-Me-Cln, Aib, or Anb; A 35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or C 6 -C 18 aryl group), Cys, or Om; and A 36 is an aromatic amino acid, Cys or a pharmaceutically acceptable salt thereof.
  • Particular embodiments include compounds has the formula: N- ⁇ -Ac-Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gin-Arg-Tyr-NH 2 (SEQ. ID. NO: 325), H-Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ. ID. NO: 326), N- ⁇ -Ac-Ala-Ser-Leu-Arg-Thr-Arg-Gin-Arg-Tyr-NH 2 (SEQ. ID.
  • N- ⁇ -Ac-Ala-Ser-Leu-Arg-His-Thi-Leu-Asn-Leu-Val-Thr-Arg-Gin-Arg-Tyr-NH 2 SEQ. ID. NO: 328
  • N- ⁇ -Ac-Tyr-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gin-Arg-Tyr-NH 2 SEQ. ID. NO: 329) or a pharmaceutically acceptable salt thereof.
  • PYY agonists have the formula: wherein the N-terminal amino acid is bounded to R 1 and R 2 ; Y is a chain of 0-4 amino acids, inclusive the C-terminal one of which is bonded to R 3 and R 4 ;
  • a 27 is Phe, Nal, Bip, Pcp, Tic, Trp, Bth, Thi, or Dip.
  • X is A 33 -A 34 -A 35 -A 36 wherein A 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or C 6 -C 18 aryl group), Cys, or Om; A 34 is Gln, Asn, Ala, Gly, N-Me-Gin, Aib, Cys, or Anb; A 35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or C 6 -C 18 aryl group), Cys, or Om; and A 36 is an aromatic amino acid, Cys, or a pharmaceutically acceptable salt thereof.
  • the compound has the formula: N- ⁇ -Ac-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ. ID. NO: 324).
  • Examplary PYY agonists include: YPAKEAPGEDASPEELSTYYASLR [im-DNP-His 26 ] (SEQ ID NO: 256) YLNLVTRZRY-NH 2 PYY(22-36) ASLRHYLNLVTRQRY-NH 2 (SEQ ID NO: 257) [Ala 32 ]PYY ASLRHYLNLV[Ala]RQRY-NH 2 (SEQ ID NO: 258) [Ala 23,32 ]PYY A[Ala]LRHYLNLV[Ala]RQRY-NN 2 (SEQ ID NO: 259) [Glu 28 ]PYY(22-36) ASLRHY[Glu]NLVTRQRY-NH 2 (SEQ ID NO: 260) N- ⁇ -Ac-PYY(22-36) N- ⁇ -Ac-ASLRHYLNLVTRORY-NH 2 (SEQ ID NO: 261) N- ⁇ -Ac[p.CL.Phe 26 ]PYY N- ⁇
  • PYY agonists include neurophilic Y Y2 receptor specific peptides having the formula: X1 (-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14) n -X15 wherein X1 is NH, CH 3 CO or one or two naturally occurring amino acids.
  • X2 is Leu, Ile or Val.
  • X3 is Arg, Lys or His.
  • X4 is His, Lys or Arg.
  • X5 is Tyr or Phe.
  • X6 is Leu, Ile or Val.
  • X7 is Asn or Gln.
  • X8 is Leu, Ile or Val.
  • X9 is Leu, Ile or Val.
  • X10 is Thr or Ser.
  • X11 is Arg, His or Lys.
  • X12 is Gln or Asn.
  • X13 is Arg, His or Lys.
  • X14 is Tyr or Phe.
  • X15 is COOH, NH 2 or one or two naturally occurring amino acids with the terminal amino acid being in the normal or carboxamide form; and n is 1 to 5. See U.S. Patent No. 5,696,093 .
  • Examplary agonists include:
  • PYY agonists have the formula:
  • R 1 is acetyl and ⁇ is --CH 2 --NH--.
  • a particular group of compounds is selected from a group consisting of N- ⁇ -Ac-[Nle 24,28,30 , Trp 27 , Nva 31 , ⁇ 35/36 ]PYY(22-36)-NH 2 , (SEQ ID NO: 302) N- ⁇ -Ac-[Nle 24,28 , Trp 27,30 , Nva 31 , ⁇ 35/36 ]PYY(22-36)-NH 2 , (SEQ ID NO: 303) N- ⁇ -Ac-[Nle 24,28,30 , Phe 27 , Nva 31 , ⁇ 35/36 ]PYY(22-36)-NH 2 , (SEQ ID NO: 304) N- ⁇ -Ac-[Nle 24,28 , Phe 27 , Trp 30 , Nva 31 , ⁇ 35/36 ]PYY(22-36)-NH 2 , (SEQ ID NO: 305) N- ⁇ -Ac-[Trp 30 , ⁇ 35/36 ]P
  • Another particular compound has the formula N- ⁇ -Ac-[Nle 24,28 , Trp 30 , Nva.sup. 31 , ⁇ 35/36 ]PYY(22-36)-NH 2 (SEQ. ID. NO: 309) or a pharmaceutically acceptable salt thereof.
  • PYY agonist has the formula (A), having one or two pseudopeptide bonds where each pseudopeptide bond is independently selected from the group consisting of --CH 2 --NH--, --C2 --S--,-CH 2 --C 2 --, --CH 2 --O-- and -CH 2 --CO--; wherein:
  • R 10 is A 17 -A 18 -A 19 -A 20 -A 21 ; where A 17 is Cys, Leu, Ile, Val, Nle, Nva, Aib, Anb or N-Me-Leu; A 18 is Cys, Ser, Thr, N-Me-Ser or N-Me-Thr; A 19 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R.sup.5, Cys or Orn; A 20 is an aromatic amino acid or Cys; A 21 is an aromatic amino acid or Cys; R 20 is A 33 -A 34 -A 35 -A 36 , A 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R 5 , Cys or Om; A 34 is Cys, Gin, Asn, Ala, Gly, N-Me-Gln, Aib or Anb
  • a particular group of compounds of the foregoing group of compounds are the compounds of the formula N-a-Ac-[Fla 27 )]PYY(25-36)-NH 2 and N-a-Ac-[Fla 27 ]PYY(22-36)-NH 2 or a pharmaceutically acceptable salt thereof.
  • Another group of PYY agonist has the formula: (I) (R 1 R 2 )-A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 -A 10 -R 30 , (III) (R 1 R 2 )-[A 5 -A 6 -A 7 -A 8 -A 9 -A 10 ] m R 30 , or a pharmaceutically acceptable salt thereof wherein ------represents an optional bond between the amino acids shown connected where each bond is independently selected from the group consisting of --S--Sonly when the amino acids connected are Cys-Cys, -CO-NH-, -CH 2 -NH- and provided that when the optional bond is it replaces the two amino acids that the optional bond is attached to; q is 1-4; m is 1 to 4; R 30 is OH or -O-R 1 , provided that when A 1 to A 7 are deleted then R 30 is also NH-R 1 where R 30 is
  • PYY and PYY agonists may be modified by well known processes such as amidation, glycosylation, acylation (e.g. acetylation), sulfation, phosphylation, cyclization, lipidization and pegylation.
  • Methods for lipidization with fatty acid derivatives of sulfhydryl-containing compounds are disclosed in U.S. Patent No. 5,936,092 ; U.S. Patent No. 6,093,692 ; and U.S. Patent No. 6,225,445 .
  • Fatty acid derivatives of sulfhydryl-containing PYY and PYY agonists comprising fatty acid-conjugated products with a disulfide linkage are employed for delivery of the PYY and PYY agonists to neuronal cells and tissues.
  • This modification markedly increases the absorption of the compounds relative to the rate of absorption of the unconjugated compounds, as well as prolonging blood and tissue retention of the compounds.
  • the disulfide linkage in the conjugate is quite labile in the cells and thus facilitates intracellular release of the intact compounds from the fatty acid moieties.
  • Fatty acids as constituents of phospholipids, make up the bulk of cell membranes. Due to their lipidic nature, fatty acids can easily partition into and interact with the cell membrane in a non-toxic way. Therefore, fatty acids represent potentially a useful carrier ligand for the delivery of proteins and peptides. Strategies that may use fatty acids in the delivery of proteins and peptides include the covalent modification of proteins and peptides and the use of fatty acid emulsions.
  • a sulfhydryl-containing PYY and PYY agonist is attached to a fatty acid derivative via a reversible, biodegradable disulfide bond.
  • a conjugate is expected to bind to the apical side of a cell membrane, reach the basolateral membrane of the GI-epithelium as a result of membrane transport and turnover, and become released into interstitial fluid as the result of disulfide bond reduction.
  • Such lipidized PYY and PYY agonist compounds have the general formula in which P is a residue derived from a PYY or PYY agonist; R 1 is hydrogen, lower alkyl or aryl; R 2 is a lipid-containing moiety and R 3 is --OH, a lipid-containing moiety or an amino acid chain comprising one or 2 amino acids and terminating in - CO 2 H or -COR 2 . See U.S. Patent No. 5,936,092 . These conjugates are particularly useful for increasing the absorption and prolonging blood and tissue retention of PYY and PYY agonists.
  • Typical alkyl groups include C 1-6 alkyl groups including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, and the like.
  • Preferred aryl groups are C 6-14 aryl groups and typically include phenyl, naphthyl, fluorenyl, phenanthryl, and anthracyl groups.
  • lipid-containing moiety refers to either a lipid group per se or a hydrocarbon-based group (in particular, one or more amino acids) comprising a lipid group.
  • lipid group is meant a hydrophobic substituent consisting of 4 to 26 carbon atoms, preferably 5 to 19 carbon atoms. Suitable lipid groups include, but are not limited to, the following: palmityl (C 15 H 31 ,), oleyl (C 15 H 29 ), stearyl (C 17 H 35 ), cholate; and deoxycholate.
  • lipidized PYY and PYY agonist compounds have general Formula I in which R 2 is selected from the group consisting of hydrogen, halo, alkyl, or aryl, wherein the alkyl or aryl groups are optionally substituted with one or more alkoxy, alkoxyalkyl, alkanoyl, nitro, cycloalkyl, alkenyl, alkynyl, alkanoyloxy, alkyl or halogen atoms; R 3 is a lipophilic group; one of R 4 and R 5 is a PYY or a PYY agonist and the other of R 4 and R 5 is OR 6 where R 6 is hydrogen, an alkali metal or a negative charge; X is oxygen or sulfur; Y is a bridging natural or un
  • Typical alkyl groups include C 1-6 alkyl groups including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, and the like.
  • Typical alkoxy groups include oxygen substituted by any of the alkyl groups mentioned above.
  • Typical alkoxyalkyl groups include any of the above alkyl groups substituted by an alkoxy group, such as methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, and the like.
  • Preferred aryl groups are C 6-14 aryl groups and typically include phenyl, naphthyl, fluorenyl, phenanthryl, and anthracyl groups.
  • Typical alkoxy substituted aryl groups include the above aryl groups substituted by one or more of the above alkoxy groups, e.g., 3-methoxyphenyl, 2-ethoxyphenyl, and the like.
  • Typical alkyl substituted aryl groups include any of the above aryl groups substituted by any of the C 1-6 alkyl groups, including the group Ph(CH 2 )n, where n is 1-6, for example, tolyl, o-, m-, and p-xylyl, ethylphenyl, 1-propylphenyl, 2-propylphenyl, 1-butylphenyl, 2-butylphenyl, t-butylphenyl, 1-pentylphenyl, 2-pentylphenyl, 3-pentylphenyl.
  • Typical alkenyl groups include C 2-6 alkenyl groups, e.g. ethenyl, 2-propenyl, isopropenyl, 2-butenyl, 3-butenyl, 4-pentenyl, 3-pentenyl, 2-pentenyl, 5-hexenyl, 4-hexenyl, 3-hexenyl, and 2-hexenyl groups.
  • Typical alkynyl groups include C 2-6 alkynyl groups e.g. enthynyl, 2-propenyl, 2-butynyl, 3-butynyl, 4-pentynyl, 3-pentynyl, 2-pentynyl, 5-hexynyl, 4hexynyl, 3-hexynyl, and 2-hexynyl groups.
  • Typical alkenyl or alkynyl substituted aryl groups include any of the above C 6-14 aryl groups substituted by any of the above C 2-6 alkenyl or C 2-6 alkynyl groups, e.g., ethenylphenyl, 1-propenylphenyl, 2-propenylphenyl, lbutenylphenyl, 2-butenylphenyl, 1-pentenylphenyl, 2-pentenylphenyl, 3-pentenylphenyl, 1-hexenylphenyl, 2-hexenylphenyl, 3-hexenylphenyl, ethynylphenyl, 1-propynylphenyl, 2-propynylphenyl, 1-butynylphenyl, 2-butynylphenyl, 1-pentynylphenyl, 2-pentynylphenyl, 3-pentynylphenyl, 1-hexyn
  • Typical halo groups include fluorine, chlorine, bromine, and iodine.
  • Typical halo substituted alkyl groups include C 1-6 alkyl groups substituted by one or more fluorine, chlorine, bromine, or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, and trichloromethyl groups.
  • Typical cycloalkyl groups include C 3-8 cycloalkyl groups including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups.
  • lipophilic group refers to either a naturally occurring lipid per se, a hydrophobic branched or unbranched hydrocarbon comprising about 4 to about 26 carbon atoms, preferably about 5 to about 19 carbon atoms, a fatty acid or ester thereof, or a surfactant.
  • Suitable lipophilic groups include, but are not limited to, long chain alkanoyl groups including: palmityl (C 15 H 31 ), oleyl (C 15 H 29 ), stearyl (C 17 H 35 ), lauryl (C 11 H 23 ), cholyl, and myristyl (C 13 H 27 )
  • natural or unnatural amino acid refers to any of the 21 naturally occurring amino acids as well as D-form amino acids, blocked L-and D-form amino acids such as those blocked by amidation or acylation, substituted amino acids (e.g., those substituted with a sterically hindered alkyl group or a cycloalkyl group such as cyclopropyl or cyclobutyl) in which the substitution introduces a conformational restraint in the amino acid.
  • amino acids or components of a peptide or protein are alanine, arginine, asparagine, aspartic acid, citrulline, cysteine, cystine, y-glutamic acid, glutamine, glycine, histidine, isoleucine, norleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, hydroxyproline, serine, threonine, tryptophan, tyrosine, valine, ⁇ -carboxyglutamate, or O-phosphoserine.
  • the preferred non-naturally occurring amino acids for use in the present disclosure as amino acids or components of peptides or proteins are any of the ⁇ -amino acids, e.g., ⁇ -alanine, ⁇ -amino butyric acid, ⁇ -amino butyric acid, ⁇ -(aminophenyl)butyric acid, ⁇ -amino isobutyric acid, ⁇ -amino caproic acid, 7-amino heptanoic acid, amino benzoic acid, aminophenyl acetic acid, aminophenyl butyric acid, cysteine (ACM), methionine sulfone, phenylglycine, norvaline, ornithine, ⁇ -ornithine, ⁇ nitro-phenylalanine, 1,2,3,4-terahydroisoquinoline-3-carboxylic acid and thioproline.
  • ⁇ -amino acids e.g., ⁇ -alanine,
  • the present disclosure is also directed to methods of preparing lipidized conjugates of PYY and PYY agonists, pharmaceutical compositions comprising lipidized conjugates of PYY and PYY agonists, and methods of increasing the delivery of amino group-containing PYY and PYY agonists into a cell.
  • modified derivatives of PYY and PYY agonists which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337 ).
  • modified derivatives include PYY and PYY agonists modified by pegylation.
  • pegylated and pegylation refer to the process of reacting a poly(alkylene glycol), preferably an activated poly(alkylene glycol), with a facilitator such as an amino acid, e.g. lysine, to form a covalent bond.
  • pegylation is often carried out using poly(ethylene glycol) or derivatives thereof, such as methoxy poly(ethylene glycol), the term is not intended to be so limited here, but is intended to include any other useful poly(alkylene glycol), such as, for example poly(propylene glycol).
  • the chemical moieties for derivitization may also be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like.
  • the polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.
  • the polymer may be of any molecular weight, and may be branched or unbranched.
  • the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing.
  • Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).
  • the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.
  • the polyethylene glycol may have a branched structure.
  • Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575 ; Morpurgo et al., Appl. Biochem. Biotechnol. 56:59-72, 1996 ; Vorobjev et al., Nucleosides Nucleotides 18:2745-2750, 1999 ; and Caliceti et al., Bioconjug. Chem. 10:638-646, 1999 .
  • polyethylene glycol molecules should be attached to the polypeptides or proteins with consideration of effects on functional or antigenic domains of the polypeptides or proteins.
  • attachment methods available to those skilled in the art, e.g., EP 0 401 384 (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035, 1992 (reporting pegylation of GM-CSF using tresyl chloride).
  • polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound.
  • the amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue.
  • Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.
  • polyethylene glycol may be attached to proteins and polypeptides via linkage to any of a number of amino acid residues.
  • polyethylene glycol can be linked to proteins and polypeptides via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues.
  • One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the polypeptide or protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein or polypeptide.
  • polyethylene glycol as an illustration, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (or peptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein.
  • the method of obtaining the N-terminally pegylated preparation i.e., separating this moiety from other monopegylated moieties if necessary
  • Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.
  • pegylation of the proteins and polypeptides may be accomplished by any number of means.
  • polyethylene glycol may be attached to the protein or polypeptide either directly or by an intervening linker.
  • Linkerless systems for attaching polyethylene glycol to proteins and polypeptides are described in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304, 1992 ; Francis et al., Intern. J. of Hematol. 68:1-18,1998 ; U.S. Patent No. 4,002,531 ; U.S. Patent No. 5,349,052 ; WO 95/06058 ; and WO 98/32466 .
  • One system for attaching polyethylene glycol directly to amino acid residues of proteins and polypeptides without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride (ClSO 2 CH 2 CF 3 ).
  • MPEG monmethoxy polyethylene glycol
  • ClSO 2 CH 2 CF 3 tresylchloride
  • polyethylene glycol is directly attached to amine groups of the protein or polypeptide.
  • the disclosure includes protein-polyethylene glycol conjugates produced by reacting proteins and polypeptides with a polyethylene glycol molecule having a 2,2,2-trifluoreothane sulphonyl group.
  • Polyethylene glycol can also be attached to proteins and polypeptides using a number of different intervening linkers.
  • U.S. Patent No. 5,612,460 discloses urethane linkers for connecting polyethylene glycol to proteins.
  • Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein or polypeptide by a linker can also be produced by reaction of proteins or polypeptides with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG- p -nitrophenolcarbonate, and various MPEG-succinate derivatives.
  • MPEG-succinimidylsuccinate MPEG activated with 1,1'-carbonyldiimidazole
  • MPEG-2,4,5-trichloropenylcarbonate MPEG- p -nitrophenolcarbonate
  • various MPEG-succinate derivatives A number of additional polyethylene glyco
  • the number of polyethylene glycol moieties attached to each protein or polypeptide may also vary.
  • the pegylated proteins and polypeptides may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules.
  • the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein or polypeptide molecule.
  • Methods for determining the degree of substitution are discussed, for example, in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304, 1992 .
  • proteins and polypeptides containing substantially non-antigenic polymers may be prepared, for example, as described in U.S. Patent No. 5,428,128 ; U.S. Patent No. 6,127,355 ; and U.S. Patent No. 5,880,131 .
  • PEG poly(ethylene glycol)
  • activation the hydroxyl end groups of the PEG must first be converted into reactive functional groups. This process is frequently referred to as “activation” and the product is called “activated PEG.”
  • Methoxy poly(ethylene glycol) (mPEG) distally capped with a reactive functional group is often used.
  • mPEG Methoxy poly(ethylene glycol)
  • SS-PEG succinimidyl succinate derivative of PEG
  • substantially non-antigenic polymers that may be employed in the practice of the present disclosure include materials such as dextran, polyvinyl pyrrolidones, polysaccharides, starches, polyvinyl alcohols, polyacrylamides, or other similar non-immunogenic polymers.
  • materials such as dextran, polyvinyl pyrrolidones, polysaccharides, starches, polyvinyl alcohols, polyacrylamides, or other similar non-immunogenic polymers.
  • the polymer is introduced into the peptide or protein molecule after being functionalized or activated for reaction and attachment to one or more amino acids.
  • activation it is understood by those of ordinary skill in the art that the polymer is functionalized to include a desired reactive group. See; for example, U.S. Patent No. 4,179,337 and U.S. Patent No. 5,122,614 .
  • the hydroxyl end groups of poly(alkylene glycols) are converted and activated into reactive functional groups.
  • the polymer is conjugated to a facilitator moiety prior to being introduced into the polypeptide or protein molecule.
  • the facilitator moiety is preferably an amino acid such as lysine, however, non-amino acid moieties are also contemplated.
  • multifunctionalized organic moieties such as alkyls or substituted alkyls. Such moieties can be prepared to have a nucleophilic functional group such as an amine and an electrophilic group such as an acid as well as a suitably functionalized region for conjugating with the desired polymer or polymers.
  • the facilitator moieties allow easier inclusion of a polymer into the peptide or protein molecule during synthesis.
  • poly(alkylene glycols) coupled to facilitator amino acids or amino acid residues in polypeptides or proteins by means of suitable coupling agents are illustrative.
  • a useful review of a number of coupling agents known in the art appears in Dreborg et al., Critical Reviews in Therapeutic Drug Carrier Systems 6(4):315-165, 1990 , see especially, pp. 317-320.
  • Pegylated PYY peptides and agonists can also be of the general formula wherein:
  • Typical alkyl groups include C 1-6 alkyl groups including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, and the like.
  • Preferred aryl groups are C 6-14 aryl groups and typically include phenyl, naphthyl, fluorenyl, phenanthryl, and anthracyl groups.
  • Typical alkyl substituted aryl groups include any of the above aryl groups substituted by any of the C 1-6 alkyl groups, including the group Ph(CH 2 ) n , where n is 1-6, for example, tolyl, o-, m-, and p-xylyl, ethylphenyl, 1-propylphenyl, 2-propylphenyl, 1-butylphenyl, 2-butylphenyl, t-butylphenyl, 1-pentylphenyl, 2-pentylphenyl, 3-pentylphenyl.
  • Typical cycloalkyl groups include C 3-8 cycloalkyl groups including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups.
  • Typical electron withdrawing groups include O, NR 1 , S, SO and SO 2 , wherein R 1 is defined above.
  • a Y receptor antagonist is a substance (typically a ligand) which binds to a Y receptor and blocks the physiological effect of a Y receptor agonist (such as, PYY, NPY, or PP (see Tables 1-3, infra ). These antagonists could be either peptide antagonist or non-peptide antagonist of PYY, NPY, or PP.
  • Peptide antagonist include modifications, mutants, fragments, and/or variants thereof, of the PYY, NPY, or PP peptide's natural amino acid sequence (e.g., by deletions, amino acid substitutions, deletions, insertions, and modifications of the N-terminal amino and/or C-terminal carboxyl group) resulting in a peptide which acts as an antagonist to a Y receptor.
  • PYY, NPY, or PP amino acid sequences may be fusion or chimera proteins which act as antagonists at the Y receptor.
  • These peptides may also be modified by processes such as, lipidation, pegylation, amidation, glycosylation, acylation, sulfation, phosphorylation, acetylation and cyclization.
  • non-peptide antagonist of the Y receptors are known in the art and are contemplated for use with this invention. (See Table 5, infra ). Any known PYY, NPY, or PP non-peptide antagonist may be useful in this invention.
  • Exemplary antagonists of the Y receptor include, but are not limited to the following:
  • Substituted amide Y receptor antagonist such as:
  • Carbazole Y receptor antagonist such as:
  • Amine and amide derivative Y receptor antagonist such as:
  • Spiroisoquinolinone derivative Y antaponist such as:
  • Triazine derivative Y receptor antagonists such as:
  • Tricyclic compound Y receptor antagonists such as:
  • Bicyclic compound Y receptor antagonists such as:
  • N-aralkylaminotetralin Y receptor antagonist such as:
  • Amide derivative Y receptor antagonist Ref: U.S. Patent No. 6,048,900
  • N-substituted aminotetralin Y receptor antagonist such as:
  • PYY when administered to humans, PYY was found to reduce appetite. When infused into humans at physiological post-prandial levels, PYY 3-36 significantly decreased appetite and reduced food intake by a third over 12 hours, and even by a third over 24 hours. Both the effect itself and the duration of the effect are surprising and unpredictable, as they occurred for many hours after the hormone had been cleared from the circulation. The effects, which are produced at physiological levels of the peptide, are strong indications that PYY acts in vivo to regulate feeding behavior.
  • peripheral administration of PYY 3-36 in the rat caused an increase of c-fos immunoreactivity in the arcuate nucleus of the hypothalamus and a decrease in hypothalamic neuropeptide Y (NPY) mRNA.
  • NPY hypothalamic neuropeptide Y
  • the natural pathway involves release of PYY from the gut, its conversion to PYY 3-36 , which acts as an agonist on the neuropeptide Y Y2 receptor (NPY Y2 receptor) in the brain.
  • the NPY Y2 receptor acts as a inhibitory pre-synaptic receptor reducing release of neuropeptide Y, which is a most potent stimulator of feeding, and also acting on the anorexigenic melanocortin systems, the result of the NPY Y2 receptor activity being to suppress appetite and decrease food intake.
  • the action of PYY 3-36 may occur in the arcuate nucleus of the hypothalamus, but other areas may be also be involved.
  • the EGFP cassette contains its own Kozak consensus translation initiation site along with SV40 polyadenylation signals downstream of the EGFP coding sequences directing proper processing of the 3' end of the EGFP mRNA.
  • the EGFP cassette was introduced by standard techniques into the 5' untranslated region of exon 2 of a mouse Pomc genomic clone containing 13 kb of 5' and 2 kb of 3' flanking sequences ( Young et al., JNeurosci 18, 6631-40, 1998 ).
  • the transgene was microinjected into pronuclei of one-cell stage embryos of C57BL/6J mice (Jackson Laboratories) as described ( Young et al., JNeurosci 18, 6631-40, 1998 ).
  • One founder was generated and bred to wildtype C57BL/6J to produce N 1 hemizygous mice.
  • N 2 and subsequent generations of mice homozygous for the transgene were also generated. The mice are fertile and have normal growth and development.
  • Immunofluorescence and GFP co-localization Anesthetized mice were perfused transcardially with 4% paraformaldehyde and free-floating brain sections prepared with a vibratome. Sections were processed for immunofluorescence and colocalization of GFP fluorescence using standard techniques. Primary antisera and their final dilutions were rabbit anti- ⁇ -endorphin, 1:2500 v/v; rabbit anti-NPY, 1:25,000 v/v (Alanex Corp.); rabbit anti-ACTH, 1:2000 v/v; and mouse anti-TH, 1:1000 v/v (Incstar).
  • Electrophysiology 200 ⁇ m thick coronal slices were cut from the ARC of four-week old male POMC-EGFP mice. Slices were maintained in (in mM) [NaCl, 126; KCl, 2.5; MgCl 2 , 1.2; CaCl 2 .2H 2 O, 2.4; NaH 2 PO 4 .H 2 O, 1.2; NaHCO 3 , 21.4; Glucose, 11.1] (Krebs) at 35°C and saturated with 95% O 2 5% CO 2 for 1 hour(hr) prior to recordings. Recordings were made in Krebs at 35° C.
  • I-V relationships for the Met-Enk currents were established using a step protocol; (-60 mV holding potential, sequentially pulsed (40 ms) from -120 to -50 mV, cells were returned to -60 mV for 2 s between voltage steps). The protocol was repeated after Met Enk addition. The net current was the difference between the two I-V relationships. This protocol was repeated in Krebs with 6.5 mM K + . I-V relationships to identify the postsynaptic leptin current were performed similarly with slow voltage ramps (5 mV/ s from-100 to -20 mV) before and 10 minutes after the addition of leptin (100 nM).
  • GABAergic IPSCs were recorded using a CsCl internal electrode solution (in mM) [CsCl, 140; Hepes, 10; MgCl 2 , 5; Bapta, 1; (Mg)-ATP, 5; (Na)GTP, 0.3]. Both mini IPSCs and large amplitude (presumably multisynaptic) IPSCs were observed in the untreated slices. TTX (1 ⁇ M) abolished large IPSCs. Data were acquired before and after addition of drug for the times indicated on the figures at a-50 mV holding potential in 2 s. sweeps every 4 s. Mini postsynaptic currents were analyzed using Axograph 4 (Axon Instruments).
  • IPSCs and excitatory postsynaptic currents were distinguished on the basis of their decay constants; additionally picrotoxin (100 ⁇ M) blocked all IPSCs. POMC neurons receive a low EPSC tone and the frequency was not modulated by any of the treatments described here.
  • mice Male Pomc-EGFP mice were studied at 5-6 weeks of age and were generated as described above. Y2r -null mice were generated using Cre -lox P mediated recombination, which results in the germline deletion of the entire coding region of the Y2 receptor. All Y2r -null mice were maintained on a mixed C57/B16-129SvJ background. Male mice aged 8-12 weeks and between 20-30 g bodyweight were kept under controlled temperature (21-23° C) and light conditions (lights on 06:00-18:00) with ad libitum access to water and food (Gordon's Speciality Stock feeds) except where stated. All studies were performed in the early light-phase (0700-0800).
  • Intraperitoneal injections Rats were accustomed to IP injection by injections of 0.5 ml saline on the two days prior to study. For all studies, animals received an IP injection of either PYY 3-36 or saline in 500 ⁇ l (for rats) or 100 ⁇ l (for mice).
  • Electrophysiology Whole cell patch clamp recordings were made from POMC neurons in the hypothalamus of 180 ⁇ m thick coronal slices from Pomc- EGFP mice, as previously reported ( Cowley et al., Nature 411, 480-484, 2001 ). "Loose cell-attached" recordings were made using extracellular buffer in the electrode solution, and maintaining seal resistance between 3-5Mohm throughout the recording. Firing rates were analysed using mini-analysis protocols (MiniAnalysis, Jaejin Software, NJ). Vehicle controls were used in this system, previously validated for the electrophysiological actions of neuropeptides ( Cowley et al., Nature 411, 480-484, 2001 ). Data were analysed by ANOVA, Neuman-Keuls posthoc comparison, and Wilcoxon Signed Rank Test.
  • hypothalamic explants Male Wistar rats were killed by decapitation and the whole brain immediately removed, mounted with the ventral surface uppermost and placed in a vibrating microtome (Biorad, Microfield Scientific Ltd., Devon, UK). A 1.7 mm slice was taken from the base of the brain to include the PVN and the ARC and immediately transferred to 1ml of artificial CSF (aCSF) ( Kim et al., J. Clin. Invest. 105, 1005-11, 2000 ) equilibrated with 95% O 2 and 5% CO 2 and maintained at 37° C.
  • aCSF artificial CSF
  • C-fos expression was measured in adult Wistar rats and Pomc-EGFP mice 2 hours after IP administration of saline or PYY 3-36 (5 ⁇ g/100g) using standard immunohistochemical techniques ( Hoffman et al., Front. Neuroendocrinol. 14, 173-213, 1993 ). Data were obtained from 3 rats and 5 mice in each group. For the Pomc-EGFP mice 5 anatomically matched arcuate nucleus sections ( Franklin et al., The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego, 1997 ) were counted from each animal, and images acquired using a Leica TSC confocal microscope ( Grove et al., Neuroscience 100, 731-40, 2000 ).
  • Plasma assays Human leptin was measured using a commercially available radioimmunoassay (RIA) (Linco Research, USA). All other plasma hormone levels were measured using established in-house RIAs ( Tarling et al., Intensive Care Med. 23, 256-260, 1997 ). Glucose concentrations were measured using a YSI 2300STAT analyser (Yellow Springs Instruments Inc., Ohio, USA). Plasma paracetamol levels were measured using an enzymatic colorimetric assay (Olympus AU600 analyzer).
  • RIA radioimmunoassay
  • PYY 3-36 was purchased from Bachem (California, USA). The Limulus Amoebocyte Lysate assay test for pyrogen was negative and the peptide was sterile on culture. Ethical approval was obtained from the Local Research Ethics Committee (project registration 2001/6094) and the study was performed in accordance with the principles of the Declaration of Helsinki. Subjects gave informed written consent.
  • Each subject was studied on two occasions with at least 1 week between each study. Volunteers filled out a food diary for three days prior to each infusion, and for the following 24 hours. All subjects fasted and drank only water from 20:00 on the evening prior to each study. Subjects arrived at 08:30 on each study day, were cannulated and then allowed to relax for 30 minutes prior to the onset of the study protocol. Blood samples were collected every 30 minutes into heparinised tubes containing 5,000 Kallikrein Inhibitor Units (0.2 ml) of aprotinin (Bayer) and centrifuged. Plasma was separated and then stored at -70° C until analysis. Subjects were infused with either saline or 0.8 pmol.kg 1 .min -1 PYY 3-36 for 90 minutes (about 72 pmol total infusion), in a double blind randomized crossover design.
  • OXIMAX OXIMAX
  • the equipment measures O 2 consumption and CO 2 production; the efficiency with which the body produces CO 2 from O 2 gives a reliable index of caloric or metabolic efficiency.
  • a similar system is used with human volunteers.
  • a strain of transgenic mice was generated expressing green fluorescent protein (EGFP Clontech), under the transcriptional control of mouse Pomc genomic sequences that include a region located between -13 kb and -2 kb required for accurate neuronal expression ( Young et al., J Neurosci 18, 6631-40, 1998 ) ( Fig. 1a ).
  • Bright green fluorescence (509 nm) was seen in the two CNS regions where POMC is produced: the ARC and the nucleus of the solitary tract.
  • Under ultraviolet (450-480 nm) excitation POMC neurons were clearly distinguished from adjacent, non-fluorescent neurons ( Fig. 1b ) visualized under infrared optics.
  • POMC-EGFP neurons in hypothalamic slices had a resting membrane potential of-40 to -45 mV and exhibited frequent spontaneous action potentials.
  • GIRK G protein coupled, inwardly-rectifying potassium channels
  • leptin not only directly depolarizes POMC neurons but also acts at GABAergic nerve terminals to reduce the release of GABA onto POMC neurons, allowing them to adopt a more depolarized resting potential.
  • the consistent depolarization of POMC cells by leptin was specific because leptin had no effect on 5 of 13 adjacent non-fluorescent cells tested ( Fig. 3e ), while it hyperpolarized 5 ( Fig. 3f ) and depolarized 3 other non-POMC neurons in the ARC.
  • leptin The electrophysiological effects of leptin reported here are consistent with leptin's biological actions; leptin rapidly causes release of ⁇ -MSH from rat hypothalami ( Kim et al., J Clin Invest 105, 1005-11, 2000 ), presumably by activating POMC neurons.
  • NPY Y2 receptors Both the leptin and NPY Y2 receptors are expressed on NPY neurons in the ARC ( Hakansson et al., J Neurosci 18, 559-72, 1998 ; Broberger et al., Neuroendocrinology 66, 393-408, 1997 ). Furthermore, activation of Y2 receptors inhibits NPY release from NPY neurons ( King et al., J Neurochem 73, 641-6, 1999 ), and presumably would also diminish GABA release from NPY/GABA terminals. This is an alternative pharmacological approach, independent of leptin, to test the hypothesized innervation of POMC neurons by GABAergic NPY neurons.
  • NPY 100 nM; Bachem
  • NPY and leptin still inhibited IPSCs in the presence of tetrodotoxin (TTX) (6 of 6 and 3 of 5 cells respectively), indicating that some of the inhibition of IPSCs was occurring through direct effects at presynaptic nerve terminals.
  • D-Trp 8 - ⁇ MSH Another pharmacological test to confirm the origin of GABAergic innervation on POMC neurons from NPY/GABA terminals was to test the effect of the recently characterized and highly selective MC3-R agonist D-Trp 8 - ⁇ MSH ( Grieco et al., J Med Chem 43, 4998-5002, 2000 ) on local GABA release.
  • D-Trp 8 - ⁇ MSH (7 nM) increased the frequency of GABAergic IPSCs (280 ⁇ 90%) recorded from 3 of 4 POMC neurons ( Fig. 4b ). It had no effect on one cell.
  • Electron microscopy confirmed the coexpression of NPY and GABA in axon terminals and revealed that these boutons established synapses on the perikarya of all 15 ARC POMC neurons analyzed (representative example, Fig. 4e ).
  • a detailed model of regulation of this circuit shows dual mechanisms of leptin action in the ARC, interactions between NPY/GABA and POMC neurons, and autoregulatory feedback from opioid and melanocortin peptides as well as NPY ( Fig. 4f ).
  • leptin directly depolarizes the POMC neurons and simultaneously hyperpolarizes the somata of NPY/GABA neurons, and diminishes release from NPY/GABA terminals. This diminished GABA release disinhibits the POMC neurons, and result in an activation of POMC neurons and an increased frequency of action potentials.
  • PYY 3-36 is a gut-derived hormone that is released postprandially in proportion to the calories ingested ( Pedersen-Bjergaard et al., Scand. J. Clin. Lab. Invest. 56, 497-503, 1996 ). The effects of peripheral administration of PYY 3-36 on feeding were investigated.
  • IP intraperitoneal injection
  • PYY 3-36 shows a 70% amino acid sequence identity to NPY and acts through NPY receptors ( Soderberg et al., J. Neurochem. 75, 908-18, 2000 ).
  • the Y2R is a putative inhibitory presynaptic receptor and is highly expressed on the arcuate NPY neurons ( Broberger et al., Neuroendocrinology 66, 393-408, 1997 ), though not on the neighboring POMC neurons.
  • PYY 3-36 is a high affinity agonist at the Y2 receptor ( Grandt et al., Regul. Pept. 51, 151-159, 1994 ).
  • peripheral PYY 3-36 inhibits food intake via the Y2R in the arcuate nucleus, an area known to be directly accessible to circulating hormones ( Kalra et al., Endocr. Rev. 20, 68-100, 1999 ).
  • PYY 3-36 inhibited daytime feeding in a dose responsive manner in fasted male wild-type mice but did not inhibit food intake in fasted male Y2r-null mice ( Figs. 7b and 7c ).
  • IIPSCs inhibitory postsynaptic currents
  • PYY 3-36 plasma concentrations increased from mean basal concentration of 8.3 ⁇ 1.0 pM to 43.5 ⁇ 3 pM during the PYY 3-36 infusion and mimicked postprandial levels ( Pedersen-Bjergaard et al., Scand. J. Clin. Lab. Invest. 56, 497-503, 1996 ; Adrian et al., Gastroenterology 89, 1070-1077, 1985 ). Post-infusion, PYY 3-36 concentrations returned to basal within 30 minutes. PYY 3-36 infusion resulted in a significant decrease in hunger scores ( Raben et al., Br. J. Nutr. 73, 517-30, 1995 ) ( Fig.
  • the data disclosed herein demonstrates that postprandial levels of PYY 3-36 inhibit food intake in more than one mammalian species (e.g. rodents and human subjects) for up to 12 hours, thereby demonstrating a role in regulation of food intake.
  • This role can be described as a long term role, such as over a period of several hours (e.g. at least two, three, four, eight, or twelve hours, or from about two to about fifteen hours).
  • This is in contrast to previously characterized gut-derived ⁇ short-term' satiety signals, e.g.
  • cholecystokinin ( Schwartz et al., Nature 404,661-671, 2000 ; Moran, Nutrition 16, 858- 865, 2000 ), the effects of which are relatively short-lived (e.g., from about 1-4 hours).
  • PYY 3-36 The failure of PYY 3-36 to inhibit food intake in the Y2r-null mice provides evidence that PYY 3-36 reduces food intake via a Y2R dependent mechanism.
  • the results disclosed herein suggest the existence of a novel gut-hypothalamic pathway in the regulation of feeding, involving postprandial PYY 3-36 acting at the arcuate Y2R.
  • PYY, and analogs thereof, such as PYY 3-36 provide novel therapeutic agents for the treatment of obesity.
  • the present invention also relates to the following sections.
  • a method for decreasing calorie intake in a subject comprising peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.
  • peripherally administering PYY or the agonist thereof comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration.
  • peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 72 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject at least 30 minutes prior to a meal.
  • peripherally administering the therapeutically effective amount of PYY or the agonist thereof comprises administering PYY or an agonist thereof to the subject in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 0.5 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal.
  • a method for decreasing appetite in a subject comprising peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the appetite of the subject.
  • peripherally administering PYY or the agonist thereof comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration.
  • peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 72 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject at least 30 minutes prior to a meal.
  • peripherally administering the therapeutically effective amount of PYY or the agonist thereof comprises administering PYY or an agonist thereof to the subject in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 45 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal.
  • a method for decreasing food intake in a subject comprising peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the food intake of the subject.
  • peripherally administering PYY or the agonist thereof comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration.
  • peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 72 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject at least 30 minutes prior to a meal.
  • peripherally administering the therapeutically effective amount of PYY or the agonist thereof comprises administering PYY or an agonist thereof to the subject in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 0.5 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal.
  • a method for decreasing calorie intake, food intake, or appetite in a human subject comprising peripherally injecting a therapeutically effective amount of PYY or an agonist thereof in a pharmaceutically acceptable carrier to the subject in a pulse dose, thereby decreasing the calorie intake, food intake, or appetite of the subject.
  • peripherally injecting comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration.
  • peripherally injecting comprises intramuscular administration.
  • a method for increasing energy expenditure in a subject comprising peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby increasing energy expenditure in the subject.
  • peripherally administering PYY or the agonist thereof comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration.
  • peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 72 pmol per kilogram body weight of the subject.
  • peripherally administering PYY or the agonist thereof comprises administering about 35 to about 135 pmol per kilogram body weight of the subject at least 30 minutes prior to a meal.
  • peripherally administering the therapeutically effective amount of PYY or the agonist thereof comprises administering PYY or an agonist thereof to the subject in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 0.5 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal.
  • peripherally administering PYY or the agonist thereof comprises administering a dose sufficient to raise the serum level of PYY or the agonist thereof to a level of to effect a reduction in caloric intake equivalent to the reduction in caloric intake caused by a postprandial level of PYY 3-36 .
  • peripherally administering PYY or the agonist thereof comprises administering a dose sufficient to raise the serum level of PYY or the agonist thereof to a level of to effect a reduction in food intake equivalent to the reduction in food intake caused by a postprandial level of PYY 3-36 .
  • peripherally administering PYY or the agonist thereof comprises administering a dose sufficient to raise the serum level of PYY or the agonist thereof to a level of to effect a reduction in calorie intake, food intake, or appetite equivalent to the reduction in calorie intake, food intake, or appetite caused by a postprandial level of PYY 3-36.
  • peripherally administering PYY or the agonist thereof comprises administering a dose sufficient to raise the serum level of PYY or the agonist thereof to a level of to effect an increase in energy expenditure equivalen to the increase in energy expenditure caused a postprandial level of PYY 3-36 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Developers In Electrophotography (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lubricants (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Lasers (AREA)
EP20080022583 2001-09-24 2002-09-24 PYY et ses agonistes pour la modification du comportement d'alimentation Withdrawn EP2050460A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32440601P 2001-09-24 2001-09-24
GBGB0200507.2A GB0200507D0 (en) 2002-01-10 2002-01-10 Appetite suppression
US39210902P 2002-06-28 2002-06-28
EP02768992A EP1499277B1 (fr) 2001-09-24 2002-09-24 Pyy3-36 pour pour la reduction ou la prevention de l'obesite

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP02768992A Division EP1499277B1 (fr) 2001-09-24 2002-09-24 Pyy3-36 pour pour la reduction ou la prevention de l'obesite

Publications (1)

Publication Number Publication Date
EP2050460A1 true EP2050460A1 (fr) 2009-04-22

Family

ID=27256373

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20080022583 Withdrawn EP2050460A1 (fr) 2001-09-24 2002-09-24 PYY et ses agonistes pour la modification du comportement d'alimentation
EP02768992A Expired - Lifetime EP1499277B1 (fr) 2001-09-24 2002-09-24 Pyy3-36 pour pour la reduction ou la prevention de l'obesite

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02768992A Expired - Lifetime EP1499277B1 (fr) 2001-09-24 2002-09-24 Pyy3-36 pour pour la reduction ou la prevention de l'obesite

Country Status (19)

Country Link
US (2) US7459432B2 (fr)
EP (2) EP2050460A1 (fr)
JP (3) JP2005508324A (fr)
KR (1) KR100989647B1 (fr)
CN (1) CN100350968C (fr)
AT (1) ATE419863T1 (fr)
AU (1) AU2002332054B2 (fr)
BR (1) BR0212985A (fr)
CA (1) CA2461345A1 (fr)
DE (1) DE60230818D1 (fr)
DK (1) DK1499277T3 (fr)
ES (1) ES2320979T3 (fr)
HK (1) HK1070281A1 (fr)
HU (1) HU228621B1 (fr)
IL (3) IL160983A0 (fr)
MX (1) MXPA04002751A (fr)
NZ (1) NZ532427A (fr)
PL (1) PL205971B1 (fr)
WO (1) WO2003026591A2 (fr)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US7396809B1 (en) 1999-02-10 2008-07-08 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003027637A2 (fr) 2001-09-24 2003-04-03 Oregon Health And Science University Evaluations des neurones dans le noyau arque pour le criblage d'agents de modification du comportement alimentaire
ATE419863T1 (de) 2001-09-24 2009-01-15 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EP1581245A2 (fr) * 2002-12-17 2005-10-05 Nastech Pharmaceutical Company Inc. Compositions et procedes permettant d'ameliorer l'administration aux muqueuses de peptides de liaison du recepteur y2, et procedes pour le traitement et la prevention de l'obesite
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
AU2004274507B2 (en) 2003-09-18 2010-08-19 Conforma Therapeutics Corporation Novel heterocyclic compounds as HSP90-inhibitors
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005077094A2 (fr) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Motifs de la famille de polypeptides pancreatiques et polypeptides les renfermant
RU2378285C2 (ru) 2004-02-11 2010-01-10 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
WO2005080424A2 (fr) * 2004-02-23 2005-09-01 Rheoscience A/S Analogues du peptide yy
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
GB0411014D0 (en) * 2004-05-18 2004-06-23 Haptogen Ltd Methods for the control treatment and management of obesity
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
NZ552558A (en) * 2004-07-12 2009-11-27 Emisphere Tech Inc Compositions for delivering peptide YY and PYY agonists
EP1799838B1 (fr) * 2004-10-07 2010-12-15 Nestec S.A. Procedes de preparation de compositions bioactives
BRPI0516574A (pt) 2004-10-08 2008-09-16 Amylin Pharmaceuticals Inc análogos do polipeptìdeo-6 da famìlia amilina (afp-6) e métodos para preparar e usar os mesmos
RU2428431C2 (ru) * 2004-12-02 2011-09-10 Домантис Лимитед Слитые конструкции лекарственного средства и конъюгаты
AU2005316524B2 (en) * 2004-12-13 2012-01-12 Amylin Pharmaceuticals, Llc Pancreatic Polypeptide Family motifs, polypeptides and methods comprising the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
PA8660701A1 (es) * 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2330124B1 (fr) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Polypeptides hybrides ayant des propriétés sélectionnables
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
CN101268096A (zh) 2005-09-21 2008-09-17 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
CA2623088A1 (fr) 2005-09-21 2007-04-12 7Tm Pharma A/S Agonistes selectifs du recepteur y4 pour applications therapeutiques
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
WO2007039318A2 (fr) * 2005-10-06 2007-04-12 Bayer Schering Pharma Aktiengesellschaft Analogues du neuropeptide y
WO2007048027A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Combinaison de composes organiques
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
WO2007085887A1 (fr) * 2006-01-27 2007-08-02 Pfizer Products Inc. Agonistes du pyy et leurs utilisations
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US8977517B2 (en) * 2006-06-05 2015-03-10 Creighton University System and methods for evaluating efficacy of appetite-affecting drugs
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
WO2008120653A1 (fr) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Dérivé d'indoledione
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (fr) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US7814038B1 (en) * 2007-12-06 2010-10-12 Dominic John Repici Feedback-tolerant method and device producing weight-adjustment factors for pre-synaptic neurons in artificial neural networks
NZ602170A (en) * 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2741125A1 (fr) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US9492505B2 (en) 2009-01-21 2016-11-15 University Of Florida Research Foundation, Inc. Satiation peptide administration
JP5767582B2 (ja) * 2009-07-02 2015-08-19 武田薬品工業株式会社 ペプチド及びその用途
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2011106273A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9278123B2 (en) 2010-12-16 2016-03-08 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
WO2012149038A1 (fr) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci
CA2868188A1 (fr) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions de peptides glp-1 et leur preparation
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
WO2014166497A2 (fr) * 2013-04-10 2014-10-16 University Of Copenhagen Peptides dérivés du neuropeptide y
EP2992008B1 (fr) * 2013-05-02 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Peptides thérapeutiques
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP4424697A2 (fr) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
US20170137486A1 (en) 2014-05-23 2017-05-18 Imperial Innovations Limited Peptide yy (pyy) analogues
CA2959208C (fr) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Derives de pyrimidine et utilisation comme inhibiteurs de .alpha.-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2987766A1 (fr) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Systemes de mise en place et de retrait d'implant
RU2726777C2 (ru) 2015-06-12 2020-07-15 Ново Нордиск А/С Селективные соединения пептида yy и их применения
KR101604212B1 (ko) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190040237A (ko) 2016-08-24 2019-04-17 조게닉스 인터내셔널 리미티드 5-ht2b 작용물질의 형성을 억제하기 위한 제제 및 그것의 사용 방법
CN109952292A (zh) 2016-10-14 2019-06-28 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US20200062823A1 (en) * 2017-05-16 2020-02-27 The University Of Chicago Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
BR112020014596A2 (pt) 2018-01-23 2020-12-08 Gila Therapeutics, Inc. Formulações, composições e métodos farmacêuticos de peptídeo yy
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
CA3097335A1 (fr) 2018-05-11 2019-11-14 Zogenix International Limited Compositions et methodes pour traiter la mort subite provoquee par la crise epileptique
BR112021009589A2 (pt) 2018-11-20 2021-08-17 Tes Pharma S.R.L. inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN113092427A (zh) * 2021-04-02 2021-07-09 南京中医药大学 异硫氰酸荧光素在标记β内啡肽中的应用

Citations (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0036676A1 (fr) 1978-03-24 1981-09-30 The Regents Of The University Of California Procédé de préparation de liposomes de taille identique et les liposomes ainsi obtenus
EP0052322A2 (fr) 1980-11-10 1982-05-26 Gersonde, Klaus, Prof. Dr. Méthode de préparation de vésicules lipidiques par traitement aux ultra-sons, utilisation de ce procédé et l'appareillage ainsi utilisé
EP0058481A1 (fr) 1981-02-16 1982-08-25 Zeneca Limited Compositions pharmaceutiques pour la libération continue de la substance active
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046A2 (fr) 1982-02-17 1983-09-07 Ciba-Geigy Ag Lipides en phase aqueuse
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A2 (fr) 1982-07-29 1984-03-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0133988A2 (fr) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Préparations pharmaceutiques contenant des peptides régulateurs à libération retardée et procédé pour leur préparation
EP0142641A2 (fr) 1983-09-26 1985-05-29 Udo Dr. Ehrenfeld Moyen et produit pour le diagnostic et la thérapie de tumeurs ainsi que pour le traitement de déficiences du système immunitaire cellulaire et humoral
EP0143949A1 (fr) 1983-11-01 1985-06-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0267050A2 (fr) 1986-11-06 1988-05-11 Research Development Foundation Aérosols contenant des liposomes et méthods pour leur production.
US4829076A (en) 1986-09-16 1989-05-09 Alkaloida Vegyeszeti Gyar Novel dihydropyridines having calcium antagonistic and antihypertensive activity
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1993009227A1 (fr) 1991-11-06 1993-05-13 Garvan Institute Of Medical Research Recepteur de neuropeptide y-y1 humain
US5284839A (en) 1990-06-28 1994-02-08 Perstorp Ab Use of inositoltrisphosphate to treat abnornal gastrointestinal motility and secretion
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
WO1995006058A1 (fr) 1993-08-24 1995-03-02 Polymasc Pharmaceuticals Plc Modification de polymere
US5428128A (en) 1993-06-21 1995-06-27 Mensi-Fattohi; Nahla Site specific synthesis of conjugated peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5604203A (en) 1993-03-29 1997-02-18 University Of Cincinnati Analogs of peptide YY and uses thereof
US5612460A (en) 1989-04-19 1997-03-18 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5668151A (en) 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5700486A (en) 1990-11-22 1997-12-23 Vectorpharma International S.P.A. Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions
US5728396A (en) 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
WO1998032466A1 (fr) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Procede de p.e.g.ylation
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5889016A (en) 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US5936092A (en) 1995-01-25 1999-08-10 The University Of Southern California Methods and compositions for lipidization of hydrophilic molecules
US5939380A (en) 1986-05-20 1999-08-17 Wang; Paul Yao-Cheung Implant preparations containing bioactive macromolecule for sustained delivery
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6046162A (en) 1988-06-28 2000-04-04 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
WO2000034236A1 (fr) 1998-12-10 2000-06-15 University Of Southern California REACTIFS LIPIDIFIANTS, SENSIBLES AU pH, AQUEUX ET REVERSIBLES, ET COMPOSITIONS ET PROCEDES D'UTILISATION CORRESPONDANTS
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
WO2000047219A2 (fr) * 1999-02-10 2000-08-17 Ontogeny, Inc. Procedes et reactifs pour traiter des troubles metaboliques du glucose
US6127355A (en) 1993-10-20 2000-10-03 Enzon, Inc. High molecular weight polymer-based prodrugs
US6140354A (en) 1998-04-29 2000-10-31 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
US6201025B1 (en) 1998-10-07 2001-03-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
WO2001076631A2 (fr) * 2000-04-10 2001-10-18 Cedars-Sinai Medical Center Technique de manipulation du transit gastro-intestinal superieur, du debit sanguin, et de la satiete permettant de traiter l'hyperalgie viscerale
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6348472B1 (en) 1999-08-26 2002-02-19 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US6372743B1 (en) 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
US6380224B1 (en) 1999-07-28 2002-04-30 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
US6391877B1 (en) 1995-12-01 2002-05-21 Synaptic Pharmaceutical Corporation Aryl sulfonamides and sulfamide derivatives and uses thereof
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
WO2002047712A2 (fr) * 2000-12-14 2002-06-20 Amylin Pharmaceuticals, Inc. Peptide yy et antagonistes de peptides yy destines au traitement des troubles du metabolisme
US6410707B2 (en) 1996-02-06 2002-06-25 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6447743B1 (en) 1998-02-10 2002-09-10 Atofina Method for preparing an aqueous hydrogen peroxide solution directly from hydrogen and oxygen

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223017A (en) * 1975-04-15 1980-09-16 Burroughs Wellcome Co. Biologically active amides
US4175122A (en) * 1975-04-15 1979-11-20 Burroughs Wellcome Co. Biologically active amides
GB1560933A (en) * 1975-04-15 1980-02-13 Wellcome Found Biologically activy polypeptides
US4220653A (en) * 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4229389A (en) 1979-03-16 1980-10-21 Thompson Marine Corporation Gas diffuser, aerator, or sparger apparatus
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
US4701441A (en) * 1985-02-11 1987-10-20 University Of Florida Methods and compositions for stimulation of appetite
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
DE69317110T2 (de) 1992-10-28 1998-10-08 Kuraray Co., Ltd., Kurashiki, Okayama Polyurethan sowie daraus hergestellte lederähnliche folie
JP2961045B2 (ja) * 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0795562A4 (fr) 1994-11-07 2000-08-09 Kyowa Hakko Kogyo Kk Nouvelle oxyntomoduline
US6001970A (en) * 1994-11-07 1999-12-14 Merck & Co., Inc Modified human neuropeptide Y1 Receptors
US5602024A (en) * 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US5965392A (en) * 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5919901A (en) * 1996-04-08 1999-07-06 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
KR100556067B1 (ko) 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 지엘피 - 1 유도체
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ES2290799T3 (es) 1996-11-12 2008-02-16 Novo Nordisk A/S Uso de peptidos glp-1.
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
EP1629849B2 (fr) * 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Compositions pharmaceutiques contenant des exendines et leurs agonistes
EP0920864A1 (fr) 1997-12-03 1999-06-09 Pfizer Products Inc. Thérapie de combinaison comprenant un beta-3 agoniste spécifique et un agent anorexigéne
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
WO1999043707A1 (fr) 1998-02-27 1999-09-02 Novo Nordisk A/S Derives de glp-1 modifies a l'extremite n-terminale
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1147094A1 (fr) 1999-01-15 2001-10-24 Novo Nordisk A/S Agonistes non peptidiques de glp-1
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
EP1177172A1 (fr) 1999-05-05 2002-02-06 Ortho-McNeil Pharmaceutical, Inc. LIGANDS DE RECEPTEURS DU NEUROPEPTIDE Y DERIVES DE 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE, UTILISES POUR LE TRAITEMENT DE L'OBESITE ET D'AUTRES ETATS PATHOLOGIQUES
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1849475A1 (fr) 1999-06-21 2007-10-31 Eli Lilly & Company Utilisation synergique des thiazolidinediones avec peptide-1 comme glucagon et agonistes correspondants pour traiter les diabètes non dépendants de l'insuline
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
US6608098B1 (en) * 1999-08-25 2003-08-19 Banyu Pharmaceutical Co., Ltd. Isoindole derivatives
AU6798000A (en) 1999-08-26 2001-03-19 Viropharma Incorporated Compounds, compositions and methods for treating influenza
WO2001035988A1 (fr) 1999-11-12 2001-05-25 Novo Nordisk A/S Utilisation d'agonistes glp-1 pour l'inhibition de la degeneration des cellules beta
BR0015843A (pt) * 1999-11-26 2002-08-27 Shionogi & Co Antagonista de y5 para npy
DK1246638T4 (da) 2000-01-10 2014-09-22 Amylin Pharmaceuticals Llc Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
DE60114996T2 (de) 2000-03-08 2006-08-10 Novo Nordisk A/S Senkung des serum cholesterols
AU2001254686A1 (en) 2000-03-16 2001-09-24 Bayer Aktiengesellschaft Regulation of human neuropeptide y-like g protein-coupled receptor
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
WO2001087335A2 (fr) 2000-05-17 2001-11-22 Eli Lilly And Company Procede d'inhibition selective de la ghreline
US6256216B1 (en) * 2000-05-18 2001-07-03 Integrated Device Technology, Inc. Cam array with minimum cell size
AU6323001A (en) 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
US6391881B2 (en) * 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
JP2004508297A (ja) 2000-07-06 2004-03-18 メタバシス・セラピューティクス・インコーポレイテッド 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US20020156010A1 (en) * 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion
WO2002066479A1 (fr) 2001-02-23 2002-08-29 Banyu Pharmaceutical Co.,Ltd. Derives de l'isoindole
WO2002067918A1 (fr) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de diallylmethylamine
PL368201A1 (en) * 2001-07-26 2005-03-21 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
ATE419863T1 (de) 2001-09-24 2009-01-15 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP2329839B1 (fr) 2002-01-10 2015-09-16 Imperial Innovations Limited Modification du comportement d'alimentation par GLP-1 et PYY
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
DK1620118T3 (da) * 2003-04-08 2014-09-29 Yeda Res & Dev Reversible pegylerede lægemidler
CN1220702C (zh) 2003-07-30 2005-09-28 北京中科亚光生物科技有限公司 促胰岛素分泌肽及其用途
WO2005035761A1 (fr) 2003-10-16 2005-04-21 Compugen Ltd. Variants d'epissage de preproglucagon, de peptide de type glucagon 1 et d'oxyntomoduline
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1891105B1 (fr) 2005-06-13 2012-04-11 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
CA2628241C (fr) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
JP5297817B2 (ja) 2006-02-22 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション オキシントモジュリン誘導体
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響

Patent Citations (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0036676A1 (fr) 1978-03-24 1981-09-30 The Regents Of The University Of California Procédé de préparation de liposomes de taille identique et les liposomes ainsi obtenus
EP0052322A2 (fr) 1980-11-10 1982-05-26 Gersonde, Klaus, Prof. Dr. Méthode de préparation de vésicules lipidiques par traitement aux ultra-sons, utilisation de ce procédé et l'appareillage ainsi utilisé
EP0058481A1 (fr) 1981-02-16 1982-08-25 Zeneca Limited Compositions pharmaceutiques pour la libération continue de la substance active
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046A2 (fr) 1982-02-17 1983-09-07 Ciba-Geigy Ag Lipides en phase aqueuse
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A2 (fr) 1982-07-29 1984-03-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0133988A2 (fr) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Préparations pharmaceutiques contenant des peptides régulateurs à libération retardée et procédé pour leur préparation
EP0142641A2 (fr) 1983-09-26 1985-05-29 Udo Dr. Ehrenfeld Moyen et produit pour le diagnostic et la thérapie de tumeurs ainsi que pour le traitement de déficiences du système immunitaire cellulaire et humoral
EP0143949A1 (fr) 1983-11-01 1985-06-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US5939380A (en) 1986-05-20 1999-08-17 Wang; Paul Yao-Cheung Implant preparations containing bioactive macromolecule for sustained delivery
US4829076A (en) 1986-09-16 1989-05-09 Alkaloida Vegyeszeti Gyar Novel dihydropyridines having calcium antagonistic and antihypertensive activity
EP0267050A2 (fr) 1986-11-06 1988-05-11 Research Development Foundation Aérosols contenant des liposomes et méthods pour leur production.
US6046162A (en) 1988-06-28 2000-04-04 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5612460A (en) 1989-04-19 1997-03-18 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5284839A (en) 1990-06-28 1994-02-08 Perstorp Ab Use of inositoltrisphosphate to treat abnornal gastrointestinal motility and secretion
US5700486A (en) 1990-11-22 1997-12-23 Vectorpharma International S.P.A. Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions
WO1993009227A1 (fr) 1991-11-06 1993-05-13 Garvan Institute Of Medical Research Recepteur de neuropeptide y-y1 humain
US5604203A (en) 1993-03-29 1997-02-18 University Of Cincinnati Analogs of peptide YY and uses thereof
US5428128A (en) 1993-06-21 1995-06-27 Mensi-Fattohi; Nahla Site specific synthesis of conjugated peptides
WO1995006058A1 (fr) 1993-08-24 1995-03-02 Polymasc Pharmaceuticals Plc Modification de polymere
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US6127355A (en) 1993-10-20 2000-10-03 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US6225445B1 (en) 1995-01-25 2001-05-01 The University Of Southern California Methods and compositions for lipidization of hydrophilic molecules
US5936092A (en) 1995-01-25 1999-08-10 The University Of Southern California Methods and compositions for lipidization of hydrophilic molecules
US5668151A (en) 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
US6391877B1 (en) 1995-12-01 2002-05-21 Synaptic Pharmaceutical Corporation Aryl sulfonamides and sulfamide derivatives and uses thereof
US5728396A (en) 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US6410707B2 (en) 1996-02-06 2002-06-25 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
WO1998032466A1 (fr) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Procede de p.e.g.ylation
US6410792B1 (en) 1997-02-14 2002-06-25 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US5889016A (en) 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6447743B1 (en) 1998-02-10 2002-09-10 Atofina Method for preparing an aqueous hydrogen peroxide solution directly from hydrogen and oxygen
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US6140354A (en) 1998-04-29 2000-10-31 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
US6201025B1 (en) 1998-10-07 2001-03-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
WO2000034236A1 (fr) 1998-12-10 2000-06-15 University Of Southern California REACTIFS LIPIDIFIANTS, SENSIBLES AU pH, AQUEUX ET REVERSIBLES, ET COMPOSITIONS ET PROCEDES D'UTILISATION CORRESPONDANTS
WO2000047219A2 (fr) * 1999-02-10 2000-08-17 Ontogeny, Inc. Procedes et reactifs pour traiter des troubles metaboliques du glucose
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
US6380224B1 (en) 1999-07-28 2002-04-30 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
US6348472B1 (en) 1999-08-26 2002-02-19 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
US6372743B1 (en) 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
WO2001076631A2 (fr) * 2000-04-10 2001-10-18 Cedars-Sinai Medical Center Technique de manipulation du transit gastro-intestinal superieur, du debit sanguin, et de la satiete permettant de traiter l'hyperalgie viscerale
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
WO2002047712A2 (fr) * 2000-12-14 2002-06-20 Amylin Pharmaceuticals, Inc. Peptide yy et antagonistes de peptides yy destines au traitement des troubles du metabolisme

Non-Patent Citations (95)

* Cited by examiner, † Cited by third party
Title
"Molecular Biology and Biotechnology: a Comprehensive Desk Reference", 1995, VCH PUBLISHERS, INC.
"The Encyclopedia of Molecular Biology", 1994, BLACKWELL SCIENCE LTD.
ABUCHOWSKI ET AL., CANCER BIOCHEM. BIOPHYS., vol. 7, 1984, pages 175 - 186
ADRIAN ET AL., GASTROENTEROLOGY, vol. 89, 1985, pages 1070 - 1077
BAGNOL ET AL., JNEUROSCI, vol. 19, 1999, pages 26
BARLOW; DIETZ, PEDIATRICS, vol. 102, 1998, pages E29
BARRACHINA ET AL., AM. J PHYSIOL., vol. 272, 1997, pages 1007 - 11
BARSH ET AL., NATURE, vol. 404, 2000, pages 644 - 651
BATTERHAM R L ET AL: "Gut hormone PYY3-36 physiologically inhibits food intake", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 418, 8 August 2002 (2002-08-08), pages 650 - 654, XP002984562, ISSN: 0028-0836 *
BENJAMIN LEWIN: "Genes V", 1994, OXFORD UNIVERSITY PRESS
BERGLUND, MM., BIOCHEM PHARMACOL, vol. 60, no. 12, 15 December 2000 (2000-12-15), pages 1815 - 22
BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 131 0
BROBERGER ET AL., NEUROENDOCRINOLOGY, vol. 66, 1997, pages 393 - 408
BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507
BUTLER ET AL., NATURE NEUROSCIENCE, vol. 4, 2001, pages 605 - 611
CALICETI ET AL., BIOCONJUG. CHEM., vol. 10, 1999, pages 638 - 646
CLAPHAM J C ET AL: "ANTI-OBESITY DRUGS: A CRITICAL REVIEW OF CURRENT THERAPIES AND FUTURE OPPORTUNITIES", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 89, no. 1, January 2001 (2001-01-01), pages 81 - 121, XP001120530, ISSN: 0163-7258 *
COWLEY ET AL., NATURE, vol. 411, 2001, pages 480 - 484
CSIFFARY ET AL., BRAIN RES, vol. 506, 1990, pages 215 - 22
DELGADO ET AL., CRIT. REV. THERA. DRUG CARRIER SYS., vol. 9, 1992, pages 249 - 304
DOODS, H.N., JPHARMACOL EXP THER, vol. 275, no. 1, October 1995 (1995-10-01), pages 136 - 42
DREBORG ET AL., CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, vol. 6, no. 4, 1990, pages 315 - 165
DUMONT ET AL., SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 19, 1993, pages 726
E. W. MARTIN, REMINGTON'S PHARMACEUTICAL SCIENCES
EDWARDS ET AL., AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 281, 2001, pages E155 - E166
EPSTEIN ET AL., PROC. NATL. ACAD SCI. U.S.A., vol. 82, 1985, pages 3688 - 3692
FOURNIER ET AL., MOL PHARRNACOL, vol. 45, no. 1, January 1994 (1994-01-01), pages 93 - 101
FRANCIS ET AL., INTERN. J. OFHEMATOL., vol. 68, 1998, pages 1 - 18
FRANKLIN ET AL.: "The Mouse Brain in Stereotaxic Coordinates", 1997, ACADEMIC PRESS
GLAUM ET AL., MOL PHARMACO, vol. 150, 1996, pages 230 - 5
GLAUM ET AL., MOL. PHARMACOL, vol. 50, 1996, pages 230 - 5
GLAUM ET AL., MOL. PHARMACOL., vol. 50, 1996, pages 230 - 5
GRANDT ET AL., REGUL. PEPT., vol. 51, 1994, pages 151 - 159
GRIECO ET AL., JMED CHEM, vol. 43, 2000, pages 4998 - 5002
GROVE ET AL., NEUROSCIENCE, vol. 100, 2000, pages 731 - 40
GRUNDEMAR ET AL., REGULATORY PEPTIDES, vol. 62, 1996, pages 131 - 136
HAKANSSON ET AL., JNEUROSCI, vol. 18, 1998, pages 559 - 72
HOFFMAN ET AL., FRONT. NEUROENDOCRINOL., vol. 14, 1993, pages 173 - 213
HORVATH ET AL., BRAIN RES, vol. 756, 1997, pages 283 - 6
HORVATH ET AL., NEUROSCIENCE, vol. 51, 1992, pages 391 - 9
HWANG ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4030 - 4034
JEQUIER, AM. J CLIN. NUTR., vol. 45, 1987, pages 1035 - 47
KALRA ET AL., ENDOCR. REV., vol. 20, 1999, pages 68 - 100
KANATANI, A., BIOCHEM BIOPHYS RES COMMUN, vol. 272, no. 1, 27 May 2000 (2000-05-27), pages 169 - 73
KELLY ET AL., NEUROENDOCRINOLOGY, vol. 52, 1990, pages 268 - 75
KENCHAIAH ET AL., N. ENGL. J. MED, vol. 347, 2002, pages 305
KIM ET AL., DIABETES, vol. 49, 2000, pages 177 - 82
KIM ET AL., J CLIN INVEST, vol. 105, 2000, pages 1005 - 11
KIM ET AL., J CLIN. INVEST., vol. 105, 2000, pages 1005 - 11
KIM ET AL., J. CLIN. INVEST., vol. 105, 2000, pages 1005 - 11
KING ET AL., J NEUROCHEM, vol. 73, 1999, pages 641 - 6
KIRBY ET AL., J MED CHEM, vol. 36, 1993, pages 3802 - 08
KIRBY ET AL., J MED CHEM, vol. 38, 1995, pages 4579 - 86
KIRBY ET AL., JMED CHEM, vol. 36, 1993, pages 385 - 393
KOPELMAN, NATURE, vol. 404, 2000, pages 635 - 43
KOPELMAN, NATURE, vol. 404, pages 635 - 43
LANGER ET AL., J BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
LEE ET AL., J PHYSIOL (LOND, vol. 515, 1999, pages 439 - 52
LEE ET AL., J. PHYSIOL (LOND, vol. 515, 1999, pages 439 - 52
LUNDBERG J.M.; MODIN A., BR J PHARMACOL, vol. 116, no. 7, December 1995 (1995-12-01), pages 2971 - 82
LYZNICKI ET AL., AM. FAM. PHYS., vol. 63, 2001, pages 2185
MALIK ET AL., EXP. HEMATOL., vol. 20, 1992, pages 1028 - 1035
MALMSTROM, LIFE SCI, vol. 69, no. 17, 14 September 2001 (2001-09-14), pages 1999 - 2005
MALMSTROM, R.E., EUR J PHARMACOL, vol. 418, no. 1-2, 20 April 2001 (2001-04-20), pages 95 - 104
MALMSTROM, R.E., LIFE SCI, vol. 69, no. 17, 14 September 2001 (2001-09-14), pages 1999 - 2005
MASSIE, N ENGL. J. MED., vol. 347, 2002, pages 358
MORAN, NUTRITION, vol. 16, 2000, pages 858 - 865
MORPURGO ET AL., APPL. BIOCHEM. BIOTECHNOL., vol. 56, 1996, pages 59 - 72
OBES. RES., vol. 6, no. 2, 1998, pages 51S - 209S
PEDERSEN-BJERGAARD ET AL., SCAND. J CLIN. LAB. INVEST., vol. 56, 1996, pages 497 - 503
PEDERSEN-BJERGAARD ET AL., SCAND. J. CLIN. LAB. INVEST., vol. 56, 1996, pages 497 - 503
POTTER ET AL., EUR. J PHARMACOL., vol. 267, 1994, pages 253 - 262
RABEN ET AL., BR. J NUTR., vol. 73, 1995, pages 517 - 30
RISSANEN ET AL., BRITISH MED. J., vol. 301, 1990, pages 835
RIST ET AL., EUR J BIOCHEM, vol. 247, 1997, pages 1019 - 1028
ROSSI M ET AL: "Central nervous system neuropeptides involved in obesity.", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 149, 2000, 2000 Springer-Verlag GmbH & Co. KG;Springer-Verlag New York Inc. Heidelberger Platz 3, D-14197, Berlin, Germany; 175 Fifth Avenue, New York, NY, 10010-7858, USA, pages 313 - 341, XP001154661, ISSN: 0171-2004 *
SAUDEK ET AL., N ENGL. J. MED., vol. 321, 1989, pages 574
SCHOBER, DA., PEPTIDES, vol. 19, no. 3, 1998, pages 537 - 42
SCHWARTZ ET AL., NATURE, vol. 404, 2000, pages 661 - 671
SEFTON, CRC CRIT. REF BIOMED. ENG., vol. 14, 1987, pages 201
SHIRAISHI ET AL., NUTRITION, vol. 15, 1999, pages 576 - 9
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556
SLUGG ET AL., NEUROENDOCRINOLOGY, vol. 72, 2000, pages 208 - 17
SMALL ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 94, 1997, pages 11686 - 91
SODERBERG ET AL., J NEUROCHEM., vol. 75, 2000, pages 908 - 18
SPANSWICK ET AL., NATURE, vol. 390, 1997, pages 521 - 5
TARLING ET AL., INTENSIVE CARE MED., vol. 23, 1997, pages 256 - 260
TREAT ET AL.: "Liposomes in the Therapy of Infectious Disease and Cancer", 1989, LISS, pages: 317 - 327
VERMA ET AL., COLD SPRING HARB. SYMP. QUANT. BIOL., vol. 51, 1986, pages 949
VOROBJEV ET AL., NUCLEOSIDES NUCLEOTIDES, vol. 18, 1999, pages 2745 - 2750
WALKER ET AL., JOURNAL OFNEUROSCIENCES, vol. 8, 1988, pages 2438 - 2446
WANG, Y. J.; HANSON, M. A., JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY, TECHNICAL REPORT NO. 10, vol. 42, 1988, pages 2S
YOUNG ET AL., JNEUROSCI, vol. 18, 1998, pages 6631 - 40

Also Published As

Publication number Publication date
US7459432B2 (en) 2008-12-02
EP1499277A2 (fr) 2005-01-26
DE60230818D1 (de) 2009-02-26
ATE419863T1 (de) 2009-01-15
KR100989647B1 (ko) 2010-10-26
HUP0600337A2 (en) 2006-08-28
HK1070281A1 (en) 2005-06-17
US8217001B2 (en) 2012-07-10
CN100350968C (zh) 2007-11-28
HU228621B1 (en) 2013-04-29
JP2005508324A (ja) 2005-03-31
AU2002332054B2 (en) 2007-11-08
BR0212985A (pt) 2005-08-30
KR20090122497A (ko) 2009-11-30
JP2010111694A (ja) 2010-05-20
JP6124565B2 (ja) 2017-05-10
IL199364A (en) 2012-02-29
NZ532427A (en) 2008-07-31
JP2013047275A (ja) 2013-03-07
CA2461345A1 (fr) 2003-04-03
WO2003026591A9 (fr) 2004-07-08
US20090209461A1 (en) 2009-08-20
PL205971B1 (pl) 2010-06-30
US20050176630A1 (en) 2005-08-11
ES2320979T3 (es) 2009-06-01
EP1499277A4 (fr) 2005-08-31
PL374270A1 (en) 2005-10-03
CN1596119A (zh) 2005-03-16
DK1499277T3 (da) 2009-05-11
WO2003026591A3 (fr) 2004-10-28
IL160983A0 (en) 2004-08-31
MXPA04002751A (es) 2005-09-08
IL160983A (en) 2010-11-30
EP1499277B1 (fr) 2009-01-07
HUP0600337A3 (en) 2011-03-28
WO2003026591A2 (fr) 2003-04-03
IL199364A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
US7459432B2 (en) Modification of feeding behavior
US8058233B2 (en) Modification of feeding behavior using PYY and GLP-1
AU2002332054A1 (en) Modification of feeding behavior
EP2329839B1 (fr) Modification du comportement d'alimentation par GLP-1 et PYY
JP2010111694A6 (ja) 摂食行動の修正
US7919329B2 (en) Method for screening for agents that affect food intake
RU2519748C2 (ru) Способ (варианты) и средство для модификации пищевого поведения
KR100949083B1 (ko) 식습관의 변화
ZA200402284B (en) Modification of feeding behavior
AU2012216406A1 (en) Modification of feeding behavior

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1499277

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126406

Country of ref document: HK

17P Request for examination filed

Effective date: 20091019

17Q First examination report despatched

Effective date: 20091111

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AXX Extension fees paid

Extension state: MK

Payment date: 20091019

Extension state: LT

Payment date: 20091019

Extension state: SI

Payment date: 20091019

Extension state: RO

Payment date: 20091019

Extension state: AL

Payment date: 20091019

Extension state: LV

Payment date: 20091019

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OREGON HEALTH AND SCIENCE UNIVERSITY

Owner name: IMPERIAL INNOVATIONS LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMPERIAL INNOVATIONS LIMITED

Owner name: OREGON HEALTH AND SCIENCE UNIVERSITY

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1126406

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161213